

Contents

HEPATITIS B	5
HEPATITIS C	8
HIV.....	29
HAE.....	37
IPF/PAH	38
NASH	40
RHEUMATOLOGY.....	44
RARE DISEASES.....	50
ARTICLES	55

CANCER

American Society of Hematology (ASH) 2019

Clinical Practice Utilization and Outcomes with Rasburicase Vs Allopurinol for Patients at High Risk of Tumor Lysis Syndrome

Authors: Janna Radtchenko, Daniel Lyons, Yvonne Barnes, Scott Milligan, and Edward Drea

DOI: [10.1182/blood-2019-124319](https://doi.org/10.1182/blood-2019-124319)

Blood 134(Supplement_1): 2203-2203

Abstract accepted at 61st American Society of Hematology, 2019
December 7-10; Orlando, Florida



HEMOPHILIA


Haemophilia the Journal of the World Federation of Hemophilia

Effects of PK-guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe Haemophilia A

Authors: Young, G, Callaghan, MU, Balasa, V, et al.

DOI: <https://doi.org/10.1111/hae.14826>

Published in *Haemophilia the Journal of the World Federation of Hemophilia*. August 8, 2023



American Thrombosis & Hemostasis Network (ATHN) 2022

Effects of Pharmacokinetic Assessment on Clinical Outcomes for Patients with Moderate to Severe Hemophilia A

Authors: Guy Young, Michael Callaghan, Vinod Balasa, Amit Soni, Sanjay Ahuja, Jonathan C. Roberts, Mindy L. Simpson, Andrew Frick, Ali G. Mokdad, Shan Xing, and Jorge Caicedo

Poster presented at: ATHN Data Summit, 2022 Oct 19-21; London, England, U.K.




International Society on Thrombosis and Hemostasis (ISTH) 2022

Effects of Pharmacokinetic Assessment on FVIII Consumption and Estimated Costs for Patients with Moderate to Severe Hemophilia A

Authors: Guy Young, Michael Callaghan, Vinod Balasa, Amit Soni, Sanjay Ahuja, Jonathan C. Roberts, Mindy L. Simpson, Andrew Frick, Ali G. Mokdad, Shan Xing, and Jorge Caicedo

[International Society on Thrombosis and Haemostasis 2022; 2022 July 9-13: Abstract PBO689](#)


Poster presented at: 30th Congress of the International Society on Thrombosis and Haemostasis, 2022 July 9-13; London, England, U.K.

**Effects of Pharmacokinetic Assessment on Clinical Outcomes for Patients with Moderate to Severe Hemophilia A**

Authors: Guy Young, Michael Callaghan, Vinod Balasa, Amit Soni, Sanjay Ahuja, Jonathan C. Roberts, Mindy L. Simpson, Andrew Frick, Ali G. Mokdad, Shan Xing, and Jorge Caicedo

[International Society on Thrombosis and Haemostasis 2022; 2022 July 9-13: Abstract PBO688](#)

Poster presented at: 30th Congress of the International Society on Thrombosis and Haemostasis, 2022 July 9-13; London, England, U.K.

**Real-World Study of Rurioctocog Alfa Pegol and Emicizumab in US Clinical Practice Among Patients with Hemophilia A**

Authors: Shawn X. Sun, Andrew Frick, Vinod Balasa, and Jonathan C. Roberts

DOI: [10.1080/17474086.2022.2112171](https://doi.org/10.1080/17474086.2022.2112171)

Published in: Expert Review of Hematology- Online Access: August 2022



American Society of Hematology (ASH) 2021

A Retrospective Descriptive Study on the Effectiveness and Usage of Emicizumab and Antihemophilic Factor (recombinant), Fc Fusion Protein in Patients with Hemophilia A in the US

Authors: Alex Cockerham, Amanda Wilson, Andrew Frick, and Pronabesh Dasmahapatra

DOI: [10.1182/blood-2021-148325](https://doi.org/10.1182/blood-2021-148325)

Poster presented at: 63rd American Society of Hematology, 2021 December 11-14; Atlanta, Georgia



Academy of Managed Care Pharmacy (AMCP) 2021 VIRTUAL

A Retrospective Study of Rurioctocog Alfa Pegol and Emicizumab Wastage, Consumption, and Costs in US Clinical Practice Among Patients with Hemophilia A**Authors:** Shawn X. Sun, Andrew FrickDOI: [10.18553/jmcp.2021.27.4-a.s1](https://doi.org/10.18553/jmcp.2021.27.4-a.s1)

Journal of Managed Care + Specialty Pharmacy 2021 Apr; 27(4-a Suppl): S47-D17


Poster presented at: AMCP Managed Care and Specialty Pharmacy Annual Meeting, 2021 Apr 12-16 and published in Journal of Managed Care + Specialty Pharmacy



European Association for Haemophilia and Allied Disorders (EAHAD) 2021 - VIRTUAL

A Retrospective Study of the Impact of Switching Patients with Haemophilia A to Rurioctocog Alfa Pegol or Emicizumab in US Practice**Authors:** Shawn X. Sun, Andrew FrickDOI: [10.1111/hae.14236](https://doi.org/10.1111/hae.14236); [ABS039](https://doi.org/10.1111/hae.14236)

ePoster presented at: European Association for Haemophilia and Allied Disorders and published in the Wiley Online Library online; 2021 February 3-5



International Society on Thrombosis and Haemostasis (ISTH) 2020 - VIRTUAL

Real-World Outcomes before and after Switching from Standard Half-Life Factor VIII to Rurioctocog Alfa Pegol in the United States**Authors:** Shawn X. Sun and Scott Milligan[Res Pract Thromb Haemost. 2020; 4 \(Suppl 1\).](https://doi.org/10.1111/1365-0740.12411)

ePoster presented at: Virtual Congress and published online only as an addendum supplement to the ISTH open access journal, Research and Practice in Thrombosis and Haemostasis (RPTH), 2020 July 12-14

**A Retrospective, Observational Study using Specialty Pharmacy Data of Rurioctocog Alfa Pegol Use in the United States****Authors:** Louis Aledort, MD, Scott Milligan, PhD, Maureen Watt, MSc, and Jason Booth, MPHDOI: [10.18553/jmcp.2020.26.4.492](https://doi.org/10.18553/jmcp.2020.26.4.492)

J Manag Care Spec Pharam, 2020 Apr;26(4):492-503.

Published in: Journal of Managed Care & Specialty Pharmacy (JMCP): April 2020



American Society of Hematology (ASH) 2019

Real-world, Age-Stratified FVIII Consumption and Bleed Outcomes Before and After Switching to Rurioctocog Alfa Pegol in a Retrospective, Observational Study Using US Specialty Pharmacy Data

Authors: Maureen Watt, Scott Milligan
 DOI: [10.1182/blood-2019-124101](https://doi.org/10.1182/blood-2019-124101)
Blood (2019) 134(Supplement_1): 2411

Poster presented at: 61st American Society of Hematology, 2019
 December 7-10; Orlando, Florida



International Society on Thrombosis and Haemostasis (ISTH) 2019

A Retrospective, Observational Study using Specialty Pharmacy data of Rurioctocog Alfa Pegol Use in the United States

Authors: Maureen Watt and Scott Milligan
 DOI: [10.1002/rth2.12229](https://doi.org/10.1002/rth2.12229)
Res Pract Thromb Haemost. 2019; 3 (Suppl 1): PB0702

Poster presented at: International Society on Thrombosis and Haemostasis Meeting, 2019 July 6-10; Melbourne, Australia




Academy of Managed Care Pharmacy (AMCP) 2018

Retrospective, Observational Study of BAX 855 in Clinical Practice in the United States

Authors: J. Booth, M. Watt, S. Milligan, and L. Aledort.
 DOI: [10.18553/jmcp.2018.24.4-a.s1](https://doi.org/10.18553/jmcp.2018.24.4-a.s1)
AMCP Managed Care & Specialty Pharmacy 2018; 24, No.4-a: D7

Poster presented at: AMCP Managed Care and Specialty Pharmacy Annual Meeting, 2018 Apr 23-26; Boston, MA



HEPATITIS B

First-Line Therapies for Hepatitis B in the United States: A 3-year Prospective and Multicenter Real-World Study after Approval of Tenofovir Alafenamide

Authors: Calvin Q. Pan, Nezam H. Afdhal, Victor Ankoma-Sey, Ho Bae, Michael P. Curry, Douglas Dieterich, Lynn Frazier, Andrew Frick, Hie-Won Hann, W. Ray Kim, Paul Kwo, Scott Milligan, Myron J. Tong, and K. Rajender Reddy
 DOI: [10.1002/hep4.1964](https://doi.org/10.1002/hep4.1964)

Published in: *Hepatology Communications*: Online April 21, 2022



The European Association for the Study of the Liver (EASL) 2020 – VIRTUAL

Longer-Term Experience with Tenofovir Alafenamide (TAF) in HBV-Infected Patients; Changes in eGFR, FIB4, ALT, and DNA Suppression

Authors: Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal

[Journal of Hepatology. August 2020; 73 \(suppl 1\): Abstract #SAT457](#)

Poster presented at: The Digital International Liver Congress 2020; 2020 Aug 27-29




Tenofovir Alafenamide (TAF) Adoption in HBV-Infected Populations; Assessment of Care in US Clinical Practice

Authors: Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal

[Journal of Hepatology. August 2020; 73 \(suppl 1\): Abstract #SAT448](#)

Poster presented at: The Digital International Liver Congress 2020; 2020 Aug 27-29



International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2020 – VIRTUAL

Hepatitis B Treatment Patterns in US Clinical Care Following Tenofovir Alafenamide (TAF) Approval

Authors: Dr. Michael P. Curry, Dr. Ho S Bae, Dr. Douglas T Dieterich, Dr. Victor AnkomaSey, Dr. K Rajender Reddy, MD, FAASLD, Prof. Calvin Q. Pan, Dr. Hie-Won L Hann, Dr. Myron J Tong, Dr. W. Ray Kim, MD, MBA, FAASLD, Dr. Paul Y Kwo, MD, Mrs. Lynn Frazier, Ms. Kimmi Cox, Dr. Scott Milligan, and Nezam H Afdhal

[DOI: 10.1016/j.jval.2020.04.484](#)

Poster presented at: VIRTUAL ISPOR 2020 May 15-20; Published in Value in Health and ISPOR site



The American Association for the Study of Liver Diseases (AASLD) 2019

Differential Tenofovir Alafenamide (TAF) Adoption in HBV-Infected Populations; Assessment of Care in US Clinical Practice

Authors: Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal

[Journal of Hepatology. October 2019; 70 \(suppl 1\): Abstract #486](#)

Poster presented at: The Liver Meeting. 70th Annual Meeting of the American Association for the Study of Liver Diseases; 2019 Nov 8-12; Boston, MA



Longer-Term Experience with Tenofovir Alafenamide (TAF) in HBV-Infected Patients; Changes in eGFR, FIB-4, ALT, and HBV DNA Suppression

Authors: K. Rajender Reddy, Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal

[Journal of Hepatology. October 2019; 70 \(suppl 1\): Abstract #487](#)

Poster presented at: The Liver Meeting. 70th Annual Meeting of the American Association for the Study of Liver Diseases; 2019 Nov 8-12; Boston, MA




International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019

Clinical Practice Experience with Tenofovir Alafenamide (TAF) for Treatment of Hepatitis B in the US

Authors: Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Janna Radtchenko, and Nezam Afdhal

[DOI: 10.1016/j.jval.2019.04.883](#)

Poster presented at: ISPOR 2019 Conference; 2019 May 18-22; New Orleans, LA



he European Association for the Study of the Liver (EASL) 2019

Effectiveness and Safety with Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice

Authors: Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Keith Spitz, and Nezam Afdhal

[DOI: 10.1016/S0618-8278\(19\)30912-0](#)

Poster presented at: The International Liver Congress. 54th Annual Meeting of the European Association for the Study of the Liver; 2019 Apr 10-14; Vienna, Austria



Asian Pacific Association for the Study of the Liver (APASL) 2019

Effectiveness and Safety with Tenofovir Alafenamide (TAF) for Hepatitis B in Patients of Asian Race in US Clinical Practice

Authors: Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Keith Spitz, and Nezam Afdhal.

[DOI: 10.1007/s12072-019-09936-5: Abstract#627](#)

Oral presented at: APASL 2019. 28th Annual Conference of the Asian Pacific Association for the Study of Liver (APASL); 2019 Feb 20-24; Manila, Philippines

Effectiveness and Safety with tenofovir alafenamide (TAF) for Hepatitis B in patients of Asian race in US clinical practice
K. Rajender Reddy, MD
Philadelphia USA

APASL 2019
MANILA

The American Association for the Study of Liver Diseases (AASLD) 2018

Treatment of Hepatitis B in the US: Real-World Evidence from the TRIO Network

Authors: Ho Bae, Michael Curry, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, and Nezam Afdhal.

[Journal of Hepatology. October 2018; 68 \(suppl 1\): Abstract #445](#)

Poster presented at: The Liver Meeting. 69th Annual Meeting of the American Association for the Study of Liver Diseases; 2018 Nov 9-13; Washington, DC

**Early Adoption of Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice: Real-World Evidence from the TRIO Network**

Authors: Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, and Nezam Afdhal

[Journal of Hepatology. October 2018; 68 \(suppl 1\): Abstract #423](#)

Poster presented at: The Liver Meeting. 69th Annual Meeting of the American Association for the Study of Liver Diseases; 2018 Nov 9-13; Washington, DC



HEPATITIS C

The European Association for the Study of the Liver (EASL) 2022

Changing HCV Patient Profiles: Insights From a Large Multinational Real-World Sofosbuvir/Velpatasvir (SOF/VEL) Dataset

Authors: A Mangia, S Fagioli, V Di Marco, S Shafran, M Khalili, S Milligan, G Papatheodoridis, D Ouzan, S Rosati, A Ramji, E Teti, M Garcia-Retortillo, F Andres, Perez Hernandez, A Wong, C Fraser, S Rodriguez-Tajes, E Jimenez Mutiloa, LE Morano Amado, J O'Loan, F Campanale, G Macedo, M Milella, C Brixko, M Buti, MF Guerra Veloz, R Ranieri, S Borgia, A Bascia, CM Fernandez Rodriguez, B Conway, V de Ledingham, M Fenech, P Ryan, I Maida, A Martins, S Scherbakovsky, I Ntalla, C Hernandez, K Vanstraelen, and J Turnes

[The International Liver Congress 2022; 2022 June 22-26](#)

Poster presented at: The International Liver Congress 2022; 2022 June 22-26; London, United Kingdom



Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders

Authors: Heiner Wedemeyer, Vito Di Marco, Montserrat Garcia-Retortillo, Elisabetta Teti, Chris Fraser, Luis Enrique Morano Amado, Sergio Rodriguez-Tajes, Silvia Acosta-Lopez, Joss O'Loan, Michele Milella, Maria Buti, Maria Fernanda Guerra-Veloz, Alnoor Ramji, Mary Fenech, Alexandra Martins, Sergio M. Borgia, Kim Vanstraelen, Michael Mertens, Candido Hernandez, Ianna Ntalla, Heribert Ramroth, and Scott Milligan

DOI: [10.3390/v14112493](https://doi.org/10.3390/v14112493)

Published in: Viruses- Online Access: November 2022



Global Hepatitis Summit (GHS) 2020/2021

Multinational Evaluation of Comedication and Drug-drug Interactions in Hepatitis C Patients Treated with Pangenotypic Direct-acting Antivirals

Authors: Stefano Fagioli, Scott Milligan, Juan Turnés, Alessandra Mangia, Andreas Hintz, Nicole Wick, Antoni Sicras, Luca DegliEsposti, Frank Tacke, Ramón Morillo, Gema Alvarez Nieto, Gero Niess, Stacey Scherbakovsky, Marinela Méndez, Hsin-Jung Lin, Kim Vanstraelen, Candido Hernandez, and Tim Umland

Poster presented at: Global Hepatitis Summit 2020/2021 - The 17th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD); 2021 June 18-20




Is the Age of Hepatitis C Patients Influencing Rapid Direct-acting Antiviral Treatment Start? Results from a Large Multinational Real-world Dataset

Authors: Juan Turnés, Alessandra Mangia, Mandana Khalili, Scott Milligan, Stefano Fagioli, Vito Di Marco, George Papatheodoridis, Stanislas Pol, Silvia Rosati, Alnoor Ramji, Elisabetta Teti, Lisa Barrett, Montserrat Garcia-Retortillo, Francisco Pérez Hernández, Alexander Wong, Chris Fraser, Sergio Rodriguez-Tajes, Elena Jiménez Mutilo, Luis Morano, Joss O'Loan, Francesca Campanale, Guilherme Macedo, Michele Milella, Christian Brixko, Maria Buti, Maria Fernanda Guerra Veloz, Roberto Ranieri, Sergio Borgia, Annalisa Bascià, Conrado M Fernandez-Rodriguez, Brian Conway, Victor De Ledinghen, Mary Fenech, Pablo Ryan, Ivana Maida, Alexandra Martins, Ioanna Ntalla, Hsin-Jung Lin, Candido Hernandez, Kim Vanstraelen, Stacey Scherbakovsky, and Stephen D Shafran


[Global Hepatitis Summit 2020/2021; 2021 June 18-20](#)

Poster presented at: Global Hepatitis Summit 2020/2021 - The 17th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD); 2021 June 18-20



Is the Gender of Hepatitis C Patients Influencing Rapid Direct-acting Antiviral Treatment Start? Results from a Large Multinational Real-world Dataset

Authors: Alessandra Mangia, Silvia Rosati, Lisa Barrett, Elisabetta Teti, Montserrat GarciaRetortillo, Elena Jiménez Mutilo, Francesca Campanale, Maria Buti, Maria Fernanda Guerra Veloz, Annalisa Bascià, Mary Fenech, Ivana Maida, Alexandra Martins, Juan Turnés, Scott Milligan, Stefano Fagioli, Vito Di Marco, Stephen D Shafran, George Papatheodoridis, Denis Ouzan, Alnoor Ramji, Francisco Pérez Hernández, Alexander Wong, Chris Fraser, Sergio Rodríguez-Tajes, Luis Morano, Joss O'Loan, Guilherme Macedo, Michele Milella, Christian Brixko, Roberto Ranieri, Sergio Borgia, Conrado M Fernandez-Rodríguez, Brian Conway, Victor De Ledinghen, Pablo Ryan, Stacey Scherbakovsky, Hsin-Jung Lin, Kim Vanstraelen, Ioanna Ntalla, Candido Hernandez, and Mandana Khalili
[Global Hepatitis Summit 2020/2021; 2021 June 18-20](#)



Poster presented at: Global Hepatitis Summit 2020/2021 - The 17th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD); 2021 June 18-20

Spanish Association for the Study of the Liver (AEEH) 2021- VIRTUAL

Eficacia de sofosbuvir/velpatasvir (SOF/VEL) en pacientes con infección crónica por VHC y trastornos psiquiátricos: resultados en práctica clínica real en 6 países

Authors: García-Retortillo M, Milligan S, Barrett L, Teti E, Wedemeyer H, Fraser C, Morano L, Rodríguez-Tajes S, Acosta-López S, O'Loan J, Milella M, Buti M, Guerra Veloz MF, Ramji A, Fernández-Rodríguez CM, Martins Figueiredo L, Fenech M, Jiménez Mutilo E, Macedo G, Maida I, Ryan P, Campanale F, Bascia A, Conway B, Ranieri R, Borgia S, De Ledinghen V, Mangia A, Mertens M, Vanstraelen K, Ntalla I, Hernández-López C, and Di Marco V
[Gastroenterol Hepatol. 2021; 44 Supl Congr 2: 32-118: Abstract #64](#)



ePoster presented at: The 46th Annual Spanish Association For the Study of the Liver; 2021 June 14-16

Prevalence of Drug-Drug Interactions with Pangenotypic Direct-Acting Antivirals for Hepatitis C and Real-World Care Management in the United States: A Retrospective Observational Study

Authors: Michael P Curry, MD, Steven L Flamm, MD, Scott Milligan, PhD, Naoky Tsai, MD, Nicole Wick, AS, Zobair Younossi, MD, and Nezam H Afdhal, MD
 DOI: [10.18553/jmcp.2021.20550](#)

Published in: Journal of Managed Care + Specialty Pharmacy: June, 2021



The American Association for the Study of Liver Diseases (AASLD) 2020 – VIRTUAL

Effectiveness of Sofosbuvir/Velpatasvir (SOF/VEL) in Patients with Chronic HCV Infection and Mental Health Disorders: Real-World Care Management from 8 Countries

Authors: Milligan S, Barrett L, Teti E, Garcia-Retortillo M, Wedemeyer H, Fraser C, Morano L, Rodriguez-Tajes S, Acosta-Lopez S, O'Loan J, Milella M, Buti M, Guerra Veloz MF, Ramji A, Fernandez-Rodriguez CM, Martins Figueiredo L, Fenech M, Jimenez Mutiloa E, Macedo G, Maida I, Ryan P, Campanale F, Bascia A, Conway B, Ranieri R, Borgia S, De Ledinghen V, Mangia A, Mertens M, Vanstraelen K, Ntalla I, Hernandez-Lopez C, and Di Marco V

[Journal of Hepatology. November 2020; 72 \(suppl 1\): Abstract #905](#)

Poster presented at: The Liver Meeting Digital Experience: American Association for the Study of Liver Diseases; 2020 Nov 13-16



The European Association for the Study of the Liver (EASL) 2020 - VIRTUAL

Drug-Drug Interactions (DDIs) with Pangenotypic Direct-Acting Antivirals (DAAs) in Patients with Hepatitis C; Understanding the Populations at Risk and Real-World Care Management

Authors: Michael Curry, Naoky Tsai, Bruce Bacon, Steven Flamm, Zobair Younossi, Scott Milligan, Nicole Wick, and Nezam Afdhal

[Journal of Hepatology. August 2020; 73 \(suppl 1\): Abstract #THU435](#)

Poster presented at: The Digital International Liver Congress 2020; 2020 Aug 27-29

**Pangenotypic Therapies Glecaprevir-Pibrentasvir (G-P) and Sofosbuvir-Velpatasvir Voxilaprevir (S-V-V) After Failure with Interferon (IFN)-Free Direct-Acting Antiviral (DAA) Treatment for Hepatitis C**

Authors: Steven Flamm, Naoky Tsai, Bruce Bacon, Michael Curry, Scott Milligan, Nicole Wick, Zobair Younossi, and Nezam Afdhal

[Journal of Hepatology. August 2020; 73 \(suppl 1\): Abstract #SAT387](#)

Poster presented at: The Digital International Liver Congress 2020; 2020 Aug 27-29



International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2020 – VIRTUAL

Real-World Effectiveness of Hepatitis C Virus (HCV) Treatment with Direct-Acting Antivirals (DAA) in Populations with Fatty Liver/Non-Alcoholic Steatohepatitis (FL/NASH), Decompensated Cirrhosis (DCC), Hepatocellular Carcinoma (HCC), and/or Post Liver Transplant (PTX)

Authors: Zobair Younossi, Bruce Bacon, Michael Curry, Steven Flamm, Andrew Frick, Scott Milligan, Janna Radtchenko, Naoky Tsai, and Nezam Afdhal

[DOI: 10.1016/j.jval.2020.04.478](#)

Poster presented at: Virtual ISPOR 2020 May 15-20; Published in Value in Health and ISPOR site



Real-World Effectiveness of Direct-Acting Antivirals (DAA) in Young Adult (18-25) and Elderly (80+) Populations with Hepatitis C (HCV)

Authors: Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Andrew Frick, Scott Milligan, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal

DOI: [10.1016/j.jval.2020.04.483](https://doi.org/10.1016/j.jval.2020.04.483)

Poster presented at: Virtual ISPOR 2020 May 15-20; Published in Value in Health and ISPOR site



Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Simple, Effective HCV Treatment: Analysis of 5552 Patients from 12 Cohorts

Authors: Alessandra Mangia, Scott Milligan, Mandana Khalili, Stefano Fagioli, Stephen D. Shafran, Fabrice Carrat, Denis Ouzan, George Papatheodoridis, Alnoor Ramji, Sergio M. Borgia, Heiner Wedemeyer, Ruggero Losappio, Francisco Perez-Hernandez, Nicole Wick, Robert S. Brown Jr, Pietro Lampertico, Karen Doucette, Ioanna Ntalla, Heribert Ramroth, Michael Mertens, Kim Vanstraelen, and Juan Turnes

DOI: [10.1111/liv.14537](https://doi.org/10.1111/liv.14537)

Published in: Liver International: May 25, 2020



Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection

Authors: Steven L. Flamm, Jens Kort, Steven E. Marx, John Strezewski, Douglas E. Dylla, Bruce Bacon, Michael P. Curry, Naoky Tsai, and Nicole Wick

DOI: [10.1007/s12325-020-01301-5](https://doi.org/10.1007/s12325-020-01301-5)

Published in: Advances in Therapy: April 11, 2020



Real-World Efficacy of Direct Acting Antiviral Therapies in Patients with HIV/HCV

Authors: Sonia Vibhakar Patel, Dushyantha T. Jayaweera†, Keri N. Althoff, Joseph J. Eron, Janna Radtchenko, Anthony Mills, Graeme Moyle, Steven Santiago, Paul E. Sax, Jason Gillman, Karam Mounzer, Richard A. Elion, and Gregory D. Huhn

DOI: [10.1371/journal.pone.0228847](https://doi.org/10.1371/journal.pone.0228847)

Published in: PLOS ONE: February 13, 2020




Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Patients with Chronic HCV Infection: A Meta-Analysis

Authors: Pietro Lampertico, Jose A. Carrion, Michael Curry, Juan Turnes, Markus Cornberg, Francesco Negro, Ashley Brown, Marcello Persico, Nicole Wick, Ariel Porcalla, Andreas Pangerl, Eric Crown, Lois Larsen, Yao Yu, Heiner Wedemeyer

[DOI: 10.1016/j.jhep.2020.01.025](https://doi.org/10.1016/j.jhep.2020.01.025)

Published in: Journal of Hepatology; February 12, 2020



The American Association for the Study of Liver Diseases (AASLD) 2019

Drug-Drug Interactions (DDIs) with Pangenotypic Direct-Acting Antivirals (DAAs) in Patients with Hepatitis C: Understanding the Populations at Risk and Real-World Care Management

Authors: Dr. Michael P. Curry, Prof. Naoky C Tsai, Dr. Bruce R Bacon, Dr. Steven L Flamm, Prof. Zobair M Younossi, MD, MPH, FAASLD, Dr. Scott Milligan, Mrs. Nicole Wick, and Nezam H Afdhal

Poster presented at: The Liver Meeting. 70th Annual Meeting of the American Association for the Study of Liver Diseases; 2019 Nov 8-12; Boston, MA



Pangenotypic Therapies Glecaprevir-Pibrentasvir (GLE-PIB) and Sofosbuvir-Velpatasvir-Voxilaprevir (SOF-VEL-VOX) After Failure with Interferon (IFN)-Free Direct-Acting Antiviral (DAA) Treatment for Hepatitis C

Authors: Steven L Flamm, Naoky C Tsai, Bruce R Bacon, Michael P. Curry, Scott Milligan, Nicole Wick, Zobair M Younossi, and Nezam H Afdhal

Poster presented at: The Liver Meeting. 70th Annual Meeting of the American Association for the Study of Liver Diseases; 2019 Nov 8-12; Boston, MA




The European AIDS Clinical Society (EACS) 2019

Untreated HCV in HIV/HCV-Coinfected US Population Despite an Abundance of Curative Therapies

Authors: R. Elion, K. Althoff, J. Eron, J. Gillman, R. Haubrich, G. Huhn, S. Milligan, A. Mills, K. Mounzer, G. Moyle, J. Radtchenko, S. Santiago, P. Sax, and D. Jayaweera

[The 17th European AIDS Clinical Society; 2019 Nov 6-9: PE19](#)

Poster presented at: The 17th European AIDS Conference; 2019 Nov 6-9; Basel, Switzerland




American College of Gastroenterology (ACG) 2019

Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adults with Chronic Hepatitis C Virus Infection: A Meta-Analysis

Authors: Markus Cornberg, Francesco Negro, Pietro Lampertico, Juan Turnes, Michael P. Curry, Ashley Brown, Heiner Wedemeyer, Jose A Carrion, Nicole Wick, Andreas Pangerl, Eric Crown, Lois Larsen, Yao Yu, and Marcello Persico

Poster presented at: American College of Gastroenterology 2019 Conference; 2019 Oct 25-29; San Antonio, Texas




Canadian Liver Meeting 2019

Global Real World Evidence of Sofosbuvir/Velpatasvir as a Simple, Effective Regimen for the Treatment of Chronic Hepatitis C: Integrated Analysis of 12 Clinical Practice Cohorts

Authors: Dr. Alessandra Mangia, Dr. Scott Milligan, Prof. Mandana Khalili, Prof. Stefano Fagioli, Dr. Stephen D. Shafran, Prof. Fabrice Carrat, Prof. Denis Ouzan, Prof. George Papatheodoridis, Dr. Sergio M Borgia, Prof. Heiner Wedemeyer, Valeria Piazzolla, Francisco Perez, Ms. Nicole Wick, Dr. Dawn Fishbein, Prof. Pietro Lampertico, Dr. Karen Doucette, Dr. Michael Mertens, Dr. Kim Vanstaalen, Dr. A. Anna Kumaraswamy, Dr. Juan Turnes

Oral presented at: Canadian Liver Meeting 2019 Conference; 2019 May 24-26; Montreal, Canada



International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019

Access to HCV Cure Under Medicaid Programs in the United States

Authors: Zobair Younossi, Bruce Bacon, Michael Curry, Steven L Flamm, Scott Milligan, Janna Radtchenko, Naoky Tsai, and Nezam Afdhal

Poster presented at: ISPOR 2019 Conference; 2019 May 18-22; New Orleans, LA



The European Association for the Study of the Liver (EASL) 2019

Access to Direct Acting Antiviral Agents in HIV/HCV Co-Infected Population in the US

Authors: Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Janna Radtchenko, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Jason Gillman, Karam Mounzer, and Rick Elion

[2019 Apr 10-Online Access](#)


Poster presented at: The International Liver Congress. 54th Annual Meeting of the European Association for the Study of the Liver; 2019 Apr 10-14; Vienna, Austria



Clinical Practice Experience with Pangenotypic Therapies Glecaprevir-Pibrentasvir and Sofosbuvir-Velpatasvir; Data from the Trio Network

Authors: Michael Curry, Bruce Bacon, Steven L Flamm, Nicole Wick, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal


Poster presented at: The International Liver Congress. 54th Annual Meeting of the European Association for the Study of the Liver; 2019 Apr 10-14; Vienna, Austria



Effectiveness of the Salvage Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in Chronic Hepatitis C; Clinical Practice Experience from the Trio Network

Authors: Bruce Bacon, Michael Curry, Steven L Flamm, Scott Milligan, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster presented at: The International Liver Congress. 54th Annual Meeting of the European Association for the Study of the Liver; 2019 Apr 10-14; Vienna, Austria



Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir (G/P) for Treatment Naïve, Noncirrhotic Patients with HIV Infection in the TRIO Network

Authors: Michael P. Curry, Jens Kort, Steven E. Marx, John Strezewski, Nicole Wick, Steven L. Flamm, Bruce Bacon, and Naoky Tsai

Published in: GastroHep Wiley Online Library: November 23, 2019



Changing Demographics Among Populations - Prescribed HCV Treatment, 2013-2017

Authors: Naoky Tsai, MD, Bruce Bacon, MD, Michael Curry, MD, Steven L. Flamm MD, Scott Milligan, PhD, Nicole Wick, AS, Zobair Younossi, MD, and Nezam Afdhal, MD

[American Journal of Managed Care](#)

Published in: American Journal of Managed Care (AJMC): July 12, 2019




The American Association for the Study of Liver Diseases (AASLD) 2018

Change in Demographics of Direct-Acting Antiviral (DAA)-Prescribed HCV Patients from 2013 to 2018: Data from 19,994 Patients in the TRIO Network

Authors: Naoky Tsai, Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Nicole Wick, Zobair Younossi and Nezam Afdhal.


Poster presented at: The Liver Meeting. 69th Annual Meeting of the American Association for the Study of Liver Diseases; 2018 Nov 9-13; Washington, DC



Effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) for Treatment Naïve, Non-Cirrhotic Patients with HCV Infection in the TRIO Health Network

Authors: Steven L. Flamm, Jens Kort, Steve Marx, John Strezewski, Bruce Bacon, Michael P. Curry, Naoky Tsai, Nicole Wick, Zobair Younossi; and Nezam Afdhal

Poster presented at: The Liver Meeting. 69th Annual Meeting of the American Association for the Study of Liver Diseases; 2018 Nov 9-13; Washington, DC



Preferences and Outcomes in Clinical Practice with Glecaprevir/Pibrentasvir (GLE-PIB), Ledipasvir/Sofosbuvir (LDV-SOF), and Sofosbuvir/Velpatasvir (SOFVEL): Data from the TRIO Network

Authors: Michael Curry, Bruce Bacon, Steven L. Flamm, Michael Marks, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster presented at: The Liver Meeting. 69th Annual Meeting of the American Association for the Study of Liver Diseases; 2018 Nov 9-13; Washington, DC



Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in Care of Chronic Hepatitis C Patients: Clinical Practice Experience from the TRIO Network

Authors: Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster presented at: The Liver Meeting. 69th Annual Meeting of the American Association for the Study of Liver Diseases; 2018 Nov 9-13; Washington, DC



Disparities in Accessing HCV Care Under Medicaid Programs Across the US: Experience from the TRIO Network

Authors: Zobair Younossi, Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Nicole Wick, Naoky Tsai, and Nezam Afdhal

Oral presentation at: The Liver Meeting. 69th Annual Meeting of the American Association for the Study of Liver Diseases; 2018 Nov 9-13; Washington, DC

Disparities in Accessing HCV Care under Medicaid Programs Across the US: Experience from the TRIO Network

Zobair Younossi¹, Bruce Bacon², Michael Curry³, Steven L. Flamm⁴, Scott Milligan⁵, Nicole Wick⁶, Naoky Tsai⁷, and Nezam Afdhal⁸


¹Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital; ²Saint Louis University School of Medicine; ³Beth Israel Deaconess Medical Center; ⁴Northwestern University Feinberg School of Medicine; ⁵TRIO Health Analytics; and ⁶University of Hawaii

Global Hepatitis Summit (GHS) 2018

Realized Durations of Direct-Acting Antivirals (DAAs) in Care of HCV in US Clinical Practice: Data from the Trio Network

Authors: Michael Curry, Bruce Bacon, Steven Flamm, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal.

Poster presented at: Global Hepatitis Summit. 2018 June 14-17; Toronto, Canada




Digestive Disease Week (DDW) 2018

Effectiveness of 8 vs. 12 Week Ledipasvir/Sofosbuvir (LDV/SOF) in Black, Treatment Naïve Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load <6mm IU/ml: Analyses of Real-World Data from the TRIO Network

Authors: Michael Curry, Bruce Bacon, Steven Flamm, Angela Landen, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal


Poster presented at: Digestive Disease Week. 2018 June 2-5; Washington, DC



Access to and Utilization of Sofosbuvir/Velpatasvir/Voxilaprevir in Care of Chronic Hepatitis C Patients: Data from the TRIO Network

Authors: Bruce Bacon, Michael Curry, Steven Flamm, John Straub, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster presented at: Digestive Disease Week. 2018 June 2-5; Washington DC




Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network

Authors: Dushwantha Jayaweera, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion

[DOI: 10.1016/S0016-5085\(18\)33931-3](https://doi.org/10.1016/S0016-5085(18)33931-3)


Poster presented at: Digestive Disease Week. 2018 June 2-5; Washington DC



Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Authors: Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Scott Milligan, Chizoba Nwankwo, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster presented at: Digestive Disease Week. 2018 June 2-5; Washington DC



Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Authors: Michael Curry, Steven Flamm, Bruce Bacon, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal.


Poster presented at: Digestive Disease Week. 2018 June 2-5; Washington DC



Impact of HCV Viral Load on Elbasvir/Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Authors: Steven Flamm, Bruce Bacon, Michael Curry, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal.

Poster presented at: Digestive Disease Week. 2018 June 2-5; Washington DC



Behavioral and Clinical Factors and Direct Acting Antiviral (DAA) Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network

Authors: Rick Elion, Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, and Karam Mounzer

[DOI: 10.1016/S0016-5085\(18\)33670-9](https://doi.org/10.1016/S0016-5085(18)33670-9)

Oral presented at: Digestive Disease Week. 2018 June 2-5; Washington DC

Behavioral and Clinical Factors and Direct Acting Antiviral (DAA) Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network

RICK ELION, GREGORY HUHN, DUSHYANTHA JAYAWEEERA, KERI ALTHOFF, JOSEPH ERON, SCOTT MILLIGAN, ANTHONY MILLS, GRAEME MOYLE, STEVEN SANTIAAGO, PAUL SAX, GENE VOSKUH, DAVID WYLES, KARAM MOUNZER


*Gregory Huhn, MD, MPH, School of Medicine, University of Washington; Keri Althoff, MD, MPH, School of Medicine, University of Washington; Joseph Eron, MD, MPH, School of Medicine, University of Washington; Scott Milligan, MD, MPH, School of Medicine, University of Washington; Anthony Mills, MD, MPH, School of Medicine, University of Washington; Graeme Moyle, MD, MPH, School of Medicine, University of Washington; Steven Santiago, MD, MPH, School of Medicine, University of Washington; Paul Sax, MD, MPH, School of Medicine, University of Washington; Gene Voskuhl, MD, MPH, School of Medicine, University of Washington; David Wyles, MD, MPH, School of Medicine, University of Washington; Karam Mounzer, MD, MPH, School of Medicine, University of Washington.

The European Association for the Study of the Liver (EASL) 2018

Effectiveness of 8 vs. 12 Week Ledipasvir/Sofosbuvir (LDV/SOF) in Black, Treatment Naïve Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load: Analyses of Real-World Data from the TRIO Network

Authors: Michael Curry, Bruce Bacon, Steven Flamm, Angela Landen, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster presented at: The International Liver Congress. 53rd Annual Meeting of the European Association for the Study of the Liver; 2018 Apr 11-15; Paris, France



Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network

Authors: Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion

[DOI: 10.1016/S0168-8278\(18\)30723-2](https://doi.org/10.1016/S0168-8278(18)30723-2)


Poster presented at: The International Liver Congress. 53rd Annual Meeting of the European Association for the Study of the Liver; 2018 Apr 11-15; Paris, France



Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network

Authors: Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion
DOI: [10.1016/S0168-8278\(18\)30735-9](https://doi.org/10.1016/S0168-8278(18)30735-9)


Poster presented at: The International Liver Congress. 53rd Annual Meeting of the European Association for the Study of the Liver; 2018 Apr 11-15; Paris, France



Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Authors: Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Scott Milligan, Chizoba Nwankwo, Nicole Wick, Zobair Younossi, and Nezam Afdhal


Poster presented at: The International Liver Congress. 53rd Annual Meeting of the European Association for the Study of the Liver; 2018 Apr 11-15; Paris, France



Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Authors: Michael Curry, Steven Flamm, Bruce Bacon, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal


Poster presented at: The International Liver Congress. 53rd Annual Meeting of the European Association for the Study of the Liver; 2018 Apr 11-15; Paris, France



Impact of HCV Viral Load on Elbasvir/Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Authors: Steven Flamm, Bruce Bacon, Michael Curry, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster presented at: The International Liver Congress. 53rd Annual Meeting of the European Association for the Study of the Liver; 2018 Apr 11-15; Paris, France



The Impact of Individual Patient Data in a Network Meta Analysis: An Investigation Into Parameter Estimation and Model Selection

Authors: Joy Leahy, Aisling O’Leary, Nezam Afdhal, Emma Gray, Scott Milligan, Malte H. Wehmeyer, and Cathal Walsh

Published in: Research Synthesis Methods: June 20, 2018



Real-world Use of Elbasvir-Grazoprevir in Patients with Chronic Hepatitis C: Retrospective Analyses from the TRIO Network

Authors: Flamm, SL, Bacon B, Cury MP, Milligan S, Nwankwo CU, Tsai N, Younossi Z, and Afdhal N

Published in: Alimentary Pharmacology & Therapeutics (AP&T): April 17, 2018



The American Association for the Study of Liver Diseases (AASLD)

Real-World Patterns of Therapy Utilization and Outcomes in 8,049 HCV Patients: Data from the TRIO Network

Authors: Steven L. Flamm, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal


Poster presented at: The Liver Meeting. 68th Annual Meeting of the American Association for the Study of Liver Diseases; 2017 Oct 20-24; Washington, DC



Drivers of Therapy Choice in Genotype 1 HCV: Analyses of Real-World Data from the TRIO Network

Authors: M. Curry, B. Bacon, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal


Poster presented at: The Liver Meeting. 68th Annual Meeting of the American Association for the Study of Liver Diseases; 2017 Oct 20-24; Washington, DC



HCV Treatment Failure in the Era of Direct-Acting Antivirals (DAAs): Analyses of Real-World Data from the TRIO Network

Authors: Bruce Bacon, Steven L. Flamm, Michael Curry, Douglas T. Dieterich, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal


Poster presented at: The Liver Meeting. 68th Annual Meeting of the American Association for the Study of Liver Diseases; 2017 Oct 20-24; Washington, DC



Cure Denied and Cure Delayed in Chronic Hepatitis C; Monitoring Non-Start Rates and Increased Time to Start Using Real-World Data from the TRIO Network

Authors: Zobair Younossi, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, and Nezam Afdhal

Poster presented at: The Liver Meeting. 68th Annual Meeting of the American Association for the Study of Liver Diseases; 2017 Oct 20-24; Washington, DC



Impact of Treatment Duration and Ribavirin (RBV) Addition on Real-World Effectiveness of Elbasvir/Grazoprevir (EBR-GZR) in Select Patient Subgroups with Genotype 1 (GT1) Chronic Hepatitis C (HCV): Retrospective Data Analyses from the TRIO Network

Authors: C. Nwankwo, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal


Poster presented at: The Liver Meeting. 68th Annual Meeting of the American Association for the Study of Liver Diseases; 2017 Oct 20-24; Washington, DC



Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR-GZR) in Treatment Naïve (TN) Genotype 1a (GT1A) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A Resistance-Associated Substitutions (RASs)

Authors: C. Nwankwo, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal

Poster presented at: The Liver Meeting. 68th Annual Meeting of the American Association for the Study of Liver Diseases; 2017 Oct 20-24; Washington, DC



Digestive Disease Week (DDW) 2017

Real-World Results in the Renaissance of HCV Care: Analyses of Treatment for 8,955 Patients from the TRIO Network

Authors: S.L. Flamm, B. Bacon, M. Curry, D. Dieterich, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal

Poster presented at: Digestive Disease Week. 2017 May 6-9; Chicago, IL



Sofosbuvir/ Velpatasvir Compared to Existing Standards of Care in GT2-6 HCV

Authors: Michael Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal


Oral presented at: Digestive Disease Week. 2017 May 6-9; Chicago, IL



Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-World Experience from the TRIO Network

Authors: N. Tsai, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, Z. Younossi, and N. Afdhal

Poster presented at: Digestive Disease Week. 2017 May 6-9; Chicago, IL



Access to HCV Care for 31,154 Patients in the United States Real-World Experience from the TRIO Network

Authors: Zobair Younossi, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, and Nezam Afdhal

Poster presented at: Digestive Disease Week. 2017 May 6-9; Chicago, IL



The European Association for the Study of the Liver (EASL) 2017

Sofosbuvir/ Velpatasvir Compared to Existing Standards of Care in GT2-6 HCV

Authors: Michael Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal


Oral presented at: The International Liver Congress. 52nd Annual Meeting of the European Association for the Study of the Liver; 2017 Apr 13-17; Amsterdam, Netherlands



Real-World Treatment Utilization and Results in the Renaissance of HCV Care: Analyses of Treatment for 8,955 Patients from the TRIO Network

Authors: S.L. Flamm, B. Bacon, M. Curry, D. Dieterich, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal


Poster presented at: The International Liver Congress. 52nd Annual Meeting of the European Association for the Study of the Liver; 2017 Apr 13-17; Amsterdam, Netherlands



Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-World Experience from the TRIO Network

Authors: N. Tsai, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, Z. Younossi, and N. Afdhal

Poster presented at: The International Liver Congress. 52nd Annual Meeting of the European Association for the Study of the Liver; 2017 Apr 13-17; Amsterdam, Netherlands



Elbasvir/Grazoprevir Effectiveness in Patients with Chronic Hepatitis C and Chronic Kidney Disease: Real-World Experience from the TRIO Network

Authors: Z. Younossi, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, C. Nwankwo, and N. Afdhal


Poster presented at: The International Liver Congress. 52nd Annual Meeting of the European Association for the Study of the Liver; 2017 Apr 13-17; Amsterdam, Netherlands



Real-World Use of Elbasvir/Grazoprevir and Outcomes in Patients with Chronic Hepatitis C: Retrospective Data Analyses from the TRIO Network

Authors: B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, C. Nwankwo, N. Tsai, Z. Younossi, and N. Afdhal

Poster presented at: The International Liver Congress. 52nd Annual Meeting of the European Association for the Study of the Liver; 2017 Apr 13-17; Amsterdam, Netherlands




The American Association for the Study of Liver Diseases (AASLD) 2016

Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA Regimens: Real-World Experience from the TRIO Network

Authors: Kevin Korenblat, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Kris V. Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster presented at: The Liver Meeting. 67th Annual Meeting of the American Association for the Study of Liver Diseases; 2016 Nov 11-15; Boston, MA




International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2016

Effectiveness of 8 or 12 week LDV/SOF in Treatment-Naïve Patients with NonCirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network

Authors: Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster presented at: ISPOR 2016. 21st Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2016 May 21-25; Washington DC



Effectiveness of 12 or 24 week LDV-SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network

Authors: Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster presented at: ISPOR 2016. 21st Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2016 May 21-25; Washington DC




Digestive Disease Week (DDW) 2016

Ledipasvir/Sofosbuvir +/- Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network

Authors: Douglas T. Dieterich, Bruce Bacon, Michael Curry, Steven L. Flamm, Lauren Guest, Kris Kowdley, Yoori Lee, Zobair Younossi, Naoky Tsai, and Nezam Afdhal

Poster presented at: Digestive Disease Week. 2016 May 21-24; San Diego, CA



Access to Therapy in Era of DAA Regimens: Real-World Experience from the TRIO Network

Authors: Douglas T. Dieterich, Bruce Bacon, Michael Curry, Steven L. Flamm, Kris Kowdley, Yoori Lee, Zobair Younossi, Naoky Tsai, and Nezam Afdhal


Poster presented at: Digestive Disease Week. 2016 May 21-24; San Diego, CA



Failure with All-oral DAA Regimens: Real-World Experience from the Trio Network

Authors: Nezam Afdhal, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster presented at: Digestive Disease Week. 2016 May 21-24; San Diego, CA




International Liver Transplantation Society (ILTS) 2016

Ledipasvir/Sofosbuvir +/- Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the TRIO Network

Authors: Steven L. Flamm, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Lauren Guest, Kris Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster presented at: ILTS 2016. 22nd Annual Congress of the International Liver Transplantation Society; 2016 May 4-7; Seoul, South Korea




The European Association for the Study of the Liver (EASL) 2016

Ledipasvir/Sofosbuvir +/- Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network


Authors: Douglas T. Dieterich, Bruce Bacon, Michael Curry, Steven L. Flamm, Lauren Guest, Kris Kowdley, Yoori Lee, Zobair Younossi, Naoky Tsai, and Nezam Afdhal

Poster presented at: The International Liver Congress. 51st Annual Meeting of the European Association for the Study of the Liver; 2016 Apr 13-17; Barcelona, Spain

**Ledipasvir/Sofosbuvir +/- Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the TRIO Network**


Authors: Steven L. Flamm, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Lauren Guest, Kris Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster presented at: The International Liver Congress. 51st Annual Meeting of the European Association for the Study of the Liver; 2016 Apr 13-17; Barcelona, Spain

**No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/Sofosbuvir (LDV/SOF): Real-World Data from 2,034 Genotype 1 Patients in the TRIO Network**

Authors: Nezam Afdhal, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster presented at: The International Liver Congress. 51st Annual Meeting of the European Association for the Study of the Liver; 2016 Apr 13-17; Barcelona, Spain




Asian Pacific Association for the Study of the Liver (APASL) 2016

Evaluation of Efficacy of Ledipasvir/Sofosbuvir for 12 weeks in a Real-Life Population of Genotype 1a and 1b HCV Patients: Data from the TRIO Network

Authors: Nezam Afdhal, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi


Poster presented at: APASL 2016. 25th Annual Conference of the Asian Pacific Association for the Study of Liver (APASL); 2016 Feb 20-24; Tokyo, Japan



Real-world Effectiveness for 12 Weeks of Ledipasvir-Sofosbuvir for Genotype 1 Hepatitis C: The TRIO Health Study

Authors: E. B. Tapper, B. R. Bacon, M. P. Curry, D. T. Dieterich, S. L. Flamm, L. E. Guest, K. V. Kowdley, Y. Lee, N. C. Tsai, Z. M. Younossi, and N. H. Afdhal


Published in: Journal of Viral Hepatitis: October 11, 2016



Evaluation of Proton Pump Inhibitor Use on Treatment Outcomes with Ledipasvir and Sofosbuvir in a Real-World Cohort Study

Authors: Elliot B. Tapper, Bruce R. Bacon, Michael P. Curry, Douglas T. Dieterich, Steven L. Flamm, Lauren E. Guest, Kris V. Kowdley, Yoori Lee, Naoky C. Tsai, Zobair M. Younossi, and Nezam H. Afdhal

Published in: Hepatology: August 17, 2016



Disparate Access to Treatment Regimens in Chronic Hepatitis C Patients: Data from the TRIO Network

Authors: Z. M. Younossi, B. R. Bacon, D. T. Dieterich, S. L. Flamm, K. Kowdley, S. Milligan, N. Tsai, and A. Nezam

Published in: Journal of Viral Hepatitis: February 3, 2016




The American Association for the Study of Liver Diseases (AASLD) 2015

Effectiveness of 8 or 12-week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network

Authors: Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster presented at: The Liver Meeting. 66th Annual Meeting of the American Association for the Study of Liver Diseases; 2015 Nov 13-17; San Francisco, CA



Effectiveness of 12 or 24 week LDV-SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network

Authors: Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi


Poster presented at: The Liver Meeting. 66th Annual Meeting of the American Association for the Study of Liver Diseases; 2015 Nov 13-17; San Francisco, CA



Failure with All-Oral DAA Regimens: Academic and Community Treatment of a Real-World Population from the TRIO Network

Authors: Naoky Tsai, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Zobair Younossi, and Nezam Afdhal

Poster presented at: The Liver Meeting. 66th Annual Meeting of the American Association for the Study of Liver Diseases; 2015 Nov 13-17; San Francisco, CA




Digestive Disease Week (DDW) 2015

Efficacy Evaluation of 24-week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV; Data from the TRIO Network

Authors: Kris Kowdley, Bruce Bacon, Douglas T. Dieterich, Eric Lawitz, Scott Milligan, Naoky Tsai, Zobair Younossi, and Steven L. Flamm


Poster presented at: Digestive Disease Week. 2015 May 16-19; Washington DC



Evaluation of Access to Care in Patients Prescribed Sofosbuvir-containing Regimens; Data from the TRIO Network

Authors: Zobair Younossi, Bruce Bacon, Douglas Dieterich, Steven Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, and Naoky Tsai


Poster presented at: Digestive Disease Week. 2015 May 16-19; Washington DC



Final Evaluation of HCV Patients Treated with 12-week Regimens Containing Sofosbuvir +/- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population

Authors: Douglas Dieterich, Bruce Bacon, Steven Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Eric Lawitz


Poster presented at: Digestive Disease Week. 2015 May 16-19; Washington DC



Comparison of Sofosbuvir +/- Simeprevir in Heterogeneous, Real-World Populations of HCV Patients over 70 years; Data from the TRIO Network

Authors: Naoky Tsai, Bruce Bacon, Steven L. Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, Zobair Younossi, Douglas T. Dieterich

Poster presented at: Digestive Disease Week. 2015 May 16-19; Washington, DC




The European Association for the Study of the Liver (EASL) 2015

Final Evaluation of HCV Patients Treated with 12-week Regimens Containing Sofosbuvir +/- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population

Authors: Douglas Dieterich, Bruce Bacon, Steven Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Eric Lawitz


Poster presented at: The International Liver Congress. 50th Annual Meeting of the European Association for the Study of the Liver; 2015 Apr 22-26; Vienna, Austria



Comparison of Sofosbuvir +/- Simeprevir in Heterogeneous, Real-World Populations of HCV Patients over 70 years; Data from the TRIO Network

Authors: Naoky Tsai, Bruce Bacon, Steven L. Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, Zobair Younossi, and Douglas T. Dieterich


Poster presented at: The International Liver Congress. 50th Annual Meeting of the European Association for the Study of the Liver; 2015 Apr 22-26; Vienna, Austria



Efficacy Evaluation of 24-week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV; Data from the TRIO Network

Authors: Kris Kowdley, Bruce Bacon, Douglas T. Dieterich, Eric Lawitz, Scott Milligan, Naoky Tsai, Zobair Younossi, and Steven L. Flamm

Poster presented at: The International Liver Congress. 50th Annual Meeting of the European Association for the Study of the Liver; 2015 Apr 22-26; Vienna, Austria




The American Association for the Study of Liver Diseases (AASLD) 2014

Evaluation of Sofosbuvir and OLYSIO-based Regimens in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population

Authors: D Dieterich, B Bacon, S Flamm, K Kowdley, S Milligan, N Tsai, Z Younossi, E Lawitz


Oral presented at: The Liver Meeting. 65th Annual Meeting of the American Association for the Study of Liver Diseases; 2014 Nov 7-11; Boston, MA



Efficacy of Sofosbuvir and Simeprevir-Based Regimens for HCV Treatment-Experienced GT1 Patients in a Real-Life Setting; Data from the TRIO Network

Authors: Bruce Bacon, Douglas Dieterich, Steven Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, Zobair Younossi, and Naoky Tsai


Poster presented at: The Liver Meeting. 65th Annual Meeting of the American Association for the Study of Liver Diseases; 2014 Nov 7-11; Boston, MA



Evaluation of Efficacy of Sofosbuvir and Simeprevir-based Regimens in a Real-Life Population of HCV Patients with Cirrhosis; Data from the TRIO Network

Authors: Steven Flamm, Bruce Bacon, Douglas Dieterich, Kris Kowdley, Eric Lawitz, Scott Milligan, Naoky Tsai, and Zobair Younossi

Poster presented at: The Liver Meeting. 65th Annual Meeting of the American Association for the Study of Liver Diseases; 2014 Nov 7-11; Boston, MA



HIV


CROI 2024

Weight Gain in People With HIV (PWH) vs People Without HIV (PWoH) Over a 3-Year Period

Authors: Richard A. Elion, Joshua Gruber, Janna Radtchenko, Paul E. Sax, Megan Dunbar, Joseph J. Eron4, Cal Cohen, Gregory Huhn, Keri N. Althoff, Grace A. McComsey

Poster presented at: CROI; 2024 March, 3-6; Denver, CO

[Online access](#)




Real-World Use of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis: Trio Health Cohort

Authors: Kenneth Mayer, Carolyn Brown, Andrew Frick, Janna Radtchenko, Gayathri Sridhar, Leigh Ragone, Jean van Wyk, Anthony Mills, Steven Santiago, Richard Elion, Vani Vannappagari

Poster presented at: CROI; 2024 March, 3-6; Denver, CO

[Online access](#)




Real-World Utilization of Cabotegravir + Rilpivirine in the US: Data From Trio Health Cohort

Authors: Joseph J. Eron, Supriya Sarkar, Andrew Frick, Janna Radtchenko, Gayathri Sridhar, Leigh Ragone, Karam Mounzer, Steven Santiago, Jean van Wyk, Richard Elion, Vani Vannappagari

Poster presented at: CROI; 2024 March, 3-6; Denver, CO

[Online access](#)



IDWeek 2023

Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine in the United States: Trio Cohort Study

Authors: Richard A. Elion, Andrew Frick, Janna Radtchenko, Supriya Sarkar, Gayathri Sridhar, Joseph J. Eron, Karam Mounzer, Jean Van Wyk, Vani Vannappagari

Poster presented at: IDWeek 2023 October 11-15; Boston, Massachusetts



Exploring Antiretroviral Therapy (ART) Switch Decisions in Clinical Setting: Trio Health Mixed Methods Study

Authors: Rick Elion, Megan Dunbar, K Rivet Amico, Joshua Gruber, Lauren Harrison, Grace McComsey, Peter Shalit, Janna Radtchenko

Poster presented at: IDWeek 2023 October 11-15; Boston, Massachusetts




12th Annual International AIDS Society Conference on HIV Science (IAS) 2023

Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine in the United States: Trio Cohort Study

Authors: R. Elion, S. Sarkar, J. Radtchenko, A. Frick, G. Sridhar, J.J. Eron, J.C. Gathe Jr., S. Santiago, J. Van Wyk, V. Vannappagari

[Online Access](#)

Poster presented at: 12th Annual International AIDS Society Conference on HIV Science July 23-26, 2023 Brisbane, Australia



International Workshop on HIV and Hepatitis Observational Databases (IWHOD) 2023

Predictors of Switching to DTG/3TC vs B/F/TAF in US Clinical Practice

Authors: Joshua Gruber, Megan Dunbar, Janna Radtchenko, Moshe Fridman, and Richard A. Elion

Poster presented at: 25th International Workshop on HIV and Hepatitis Observational Databases 2023. 2023 Mar 23-25



Conference on Retroviruses and Opportunistic Infections (CROI) 2023

What Influences Switching to DTG/3TC VS B/F/TAF in Clinical Practice?

Authors: Paul E. Sax, Joseph J. Eron, Janna Radtchenko, Megan Dunbar, Joshua Gruber, Moshe Fridman, Steven Santiago, Moti Ramgopal, Karam Mounzer, Gregory Huhn, and Richard A. Elion

[CROI Publications Database](#)

Poster presented at: CROI 2023. Annual Conference on Retroviruses and Opportunistic Infections; 2023 Feb 19-22



HIV Glasgow 2022

Prescription Adherence and Persistence on Oral Pre-exposure Prophylaxis (PrEP) Among Prep-Naïve (PN) Individuals After FTC/TAF Approval in the United States (US)

Authors: Richard A. Elion, Joshua Gruber, Janna Radtchenko, Megan Dunbar, Kenneth H. Mayer, Gregory Huhn, Karam Mounzer, and Anthony Mills

[DOI: 10.1002/jia2.26009; P009](#)

Poster presented at: HIV Glasgow 2022. 2022 October 23-26;
Published in Journal of the International AIDS Society and Glasgow site



Characteristics of Heavily Treatment Experienced (HTE) People with HIV (PWH) in US Clinical Practice

Authors: Joseph J Eron, Megan S Dunbar, Janna Radtchenko, Joshua Gruber, Gregory Huhn, Grace A McComsey, Lauren Temme, and Richard A. Elion

[DOI: 10.1002/jia2.26009; P092](#)

Poster presented at: HIV Glasgow 2022. 2022 October 23-26;
Published in Journal of the International AIDS Society and Glasgow site



IDWeek 2022

Prescription Adherence and Persistence on Oral Pre-exposure Prophylaxis (PrEP) Among PrEP-Naïve (PN) Individuals After FTC/TAF Approval in the United States (US)

Authors: Richard A. Elion, Joshua Gruber, Janna Radtchenko, Megan Dunbar, Kenneth H. Mayer, Gregory Huhn, Karam Mounzer, and Anthony Mills

[ID Week; 2022 October 19-23; Poster 2087](#)

Poster presented at: IDWeek 2022. 2022 October 19-23; Published in IDWeek site



International AIDS Conference 2022

Utilization of Oral Pre-exposure Prophylaxis (PrEP) After FTC/TAF Approval in the United States

Authors: Richard A. Elion, Joshua Gruber, Janna Radtchenko, Megan Dunbar, Kenneth H. Mayer, Gregory Huhn, and Karam Mounzer
[24th International AIDS Conference; 2022 July 29-August 2: EPC332](#)

Poster presented at: The 24th International AIDS Conference; 2022 July 29- August 2; Montreal, Canada, and virtually




IDWeek 2021 – VIRTUAL

Virologic Failure Among Treatment-Experienced Suppressed People with HIV (PWH) Treated with Single-Tablet 2-Drug (2DR) VS 3-Drug (3DR) Regimens

Authors: Paul E. Sax, Joseph J. Eron, Janna Radtchenko, Helena Diaz-Cuervo, Mark Moore, Steven Santiago, Moti Ramgopal, Karam Mounzer, and Richard A. Elion
[ID Week Virtual; 2021 September 29- October 3](#)

Oral presented at: IDWeek 2021 VIRTUAL. 2021 September 29-October 3; Published in IDWeek site



The American Conference For The Treatment Of HIV (ACTHIV) 2021 – VIRTUAL

Variables Associated with Lack of Suppression on Antiretroviral Therapy (ART) Among People Living with Human Immunodeficiency Virus (PLWH) in the US

Authors: Richard A Elion, MD, Joe J Eron, MD, Julie Priest, MSPH, Janna Radtchenko, MBA, Moti Rampogal, MD, Alan Oglesby, MPH, and M Keith Rawlings, MD
[ACTHIV Presentation s Database](#)

ePoster presented at: Virtual ACTHIV 2021 Conference. 2021 May 20-22. Abstract was also published in The NMA Journal- 112 (5 Supplement) (pp S25), October 2020



International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 – VIRTUAL

Understanding Real-World Utilization of Pre-Exposure Prophylaxis (PrEP): Data from Trio Health HIV Research Network

Authors: Janna Radtchenko, MBA, and Rick Elion, MD
 DOI: [10.1016/j.jval.2021.04.1268](#)

ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20. Published in Value in Health and ISPOR site



Conference on Retroviruses and Opportunistic Infections (CROI) 2021- VIRTUAL

Weight Gain After Switching Different Integrase Strand Transfer Inhibitors (INSTI)

Authors: Grace A. McComsey, MD, Paul E. Sax, Keri N. Althoff, Janna Radtchenko, Helena Diaz-Cuervo, Joshua Gruber, Moti Ramgopal, Steven Santiago, Graeme Moyle, Karam Mounzer, and Richard A. Elion

[CROI 2021 Abstract eBook: Page 190-#503](#)

Oral presented at: VIRTUAL CROI 2021. Annual Conference on Retroviruses and Opportunistic Infections; 2021 Mar 6-10



IDWeek 2020 – VIRTUAL

Regional and Racial Disparities in Response to Antiretroviral Therapy (ART) Among People Living with Human Immunodeficiency Virus (PLWH)

Authors: M Keith Rawlings, MD Additional **Authors:** Joe J Eron, MD, Julie Priest, MSPH, Janna Radtchenko, MBA, Joe Mrus, MD, Moti Ramgopal, MD, Alan Oglesby, MPH, Faith Fletcher, PhD, and Richard A Elion, MD

[ID Week Virtual; 2020 October 21-25: 1704](#)

Poster presented at: IDWeek 2020 VIRTUAL. 2020 October 21-25; Published in Open Forum Infectious Diseases and IDWeek site

**Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)**

Authors: Grace A. McComsey, Paul E. Sax, Keri N. Althoff, Todd T. Brown, Janna Radtchenko, Helena Diaz-Cuervo, Moti Ramgopal, Steven Santiago, Graeme Moyle, Karam Mounzer, and Richard A. Elion

[ID Week Virtual; 2020 October 21-25: LB-7](#)

Oral presented at: IDWeek 2020 VIRTUAL. 2020 October 21-25; Published in Open Forum Infectious Diseases and IDWeek site



HIV Glasgow 2020 - VIRTUAL

Impact of Adherence on Viral Suppression with Bictegravir and Dolutegravir (DTG)- Containing Triple Therapy in Clinical Practice

Authors: Paul E. Sax, Keri N. Althoff, Joseph J. Eron, Janna Radtchenko, Helena Diaz-Cuervo, Karam Mounzer, Moti Ramgopal, Steven Santiago, and Richard A. Elion

[DOI: 10.1002/jia.2.25616: P029](#)

Poster presented at: HIV Glasgow VIRTUAL. 2020 October 5-8; Published in Journal of the International AIDS Society and Glasgow site



International AIDS Conference (IAS) 2020 – VIRTUAL

Characteristics of Patients Living With HIV (PLWH) and HIV Treatment Outcomes in Community Practices in Southern Vs Non-Southern US Regions

Authors: Keith Rawlings, MD, Paul Sax, MD, Julie Priest MSPH, Janna Radtchenko, MBA, Joe Mrus, MD, Joe Eron, MD, Alan Oglesby, MPH, Keri Althoff, PhD, Faith Fletcher, PhD, Moti Ramgopal, MD, Steven Santiago, MD, Richard A Elion, MD

[23rd International AIDS Conference Virtual; 2020 July 6-10: PEB0354](#)

Poster presented at: VIRTUAL 23rd International AIDS Conference; 2020 July 6-10



International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2020- VIRTUAL

Patterns of Adherence in Bictegravir and Dolutegravir-Based Regimens

Authors: Paul E. Sax, Joseph J. Eron, Andrew Frick, Scott Milligan, Moti Ramgopal, Steven Santiago, Richard A. Elion

[Value in Health. Volume 23, Supplement 1, S168, May 01, 2020](#)

Poster presented at: VIRTUAL ISPOR 2020 May 18-20; Published in Value in Health and ISPOR site




Conference on Retroviruses and Opportunistic Infections (CROI) 2020- VIRTUAL

Patterns of Adherence in Bictegravir and Dolutegravir-Based Regimens

Authors: Paul E. Sax, Joseph J. Eron, Andrew Frick, Scott Milligan, Moti Ramgopal, Steven Santiago, and Richard A. Elion

[The Conference on Retroviruses and Opportunistic Infections \(CROI\) Virtual; 2020 Mar 8-11: 495](#)

Poster presented at: VIRTUAL CROI 2020. Annual Conference on Retroviruses and Opportunistic Infections; 2020 Mar 8-11



Do Prescribing Data Reflect Actual Treatment in People With HIV?

Authors: Joseph J. Eron, Dushyantha Jayaweera, Gregory D. Huhn, Kelsey Milligan, Scott Milligan, Paul E. Sax, Keith Spitz, and Richard A. Elion

[The Conference on Retroviruses and Opportunistic Infections \(CROI\) Virtual; 2020 Mar 8-11: 499](#)


Poster presented at: VIRTUAL CROI 2020. Annual Conference on Retroviruses and Opportunistic Infections; 2020 Mar 8-11



Understanding Who Does and Does Not Gain Weight With Integrase Inhibitors (INSTI)

Authors: Grace A. McComsey, Keri N. Althoff, Todd T. Brown, Joseph J. Eron, Gregory D. Huhn, Anthony Mills, Graeme Moyle, Soodi Navadeh, Janna Radtchenko, Paul E. Sax, and Richard A. Elion
[The Conference on Retroviruses and Opportunistic Infections \(CROI\) Virtual; 2020 Mar 8-11: 676](#)

Poster presented at: VIRTUAL CROI 2020. Annual Conference on Retroviruses and Opportunistic Infections; 2020 Mar 8-11



Real-World Efficacy of Direct Acting Antiviral Therapies in Patients with HIV/HCV

Authors: Sonia Vibhakar Patel, Dushyantha T. Jayaweera†, Keri N. Althoff, Joseph J. Eron, Janna Radtchenko, Anthony Mills, Graeme Moyle, Steven Santiago, Paul E. Sax, Jason Gillman, Karam Mounzer, Richard A. Elion, and Gregory D. Huhn DOI: [10.1371/journal.pone.0228847](https://doi.org/10.1371/journal.pone.0228847)

Published in: PLOS ONE: February 13, 2020




The European AIDS Clinical Society (EACS) 2019

Untreated HCV in HIV/HCV-Coinfected US Population Despite an Abundance of Curative Therapies

Authors: R. Elion, K. Althoff, J. Eron, J. Gillman, R. Haubrich, G. Huhn, S. Milligan, A. Mills, K. Mounzer, G. Moyle, J. Radtchenko, S. Santiago, P. Sax, and D. Jayaweera
[The 17th European AIDS Clinical Society; 2019 Nov 6-9; Basel, Switzerland: PE19](#)

Poster presented at: The 17th European AIDS Conference; 2019 Nov 6-9; Basel, Switzerland



The European Association for the Study of the Liver (EASL) 2019

Access to Direct Acting Antiviral Agents in HIV/HCV Co-Infected Population in the US

Authors: Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Janna Radtchenko, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Jason Gillman, Karam Mounzer, and Rick Elion
[Online Access](#)

Poster presented at: The International Liver Congress. 54th Annual Meeting of the European Association for the Study of the Liver; 2019 Apr 10-14; Vienna, Austria



Conference on Retroviruses and Opportunistic Infections (CROI) 2019

Weight Gain During Treatment Among 3,468 Treatment-Experienced Adults with HIV

Authors: Grace A McComsey, Joseph J Eron, Steven Santiago, Karam Mounzer, Graeme Moyle, Thanos Vanig, Paul E Sax, Keri N Althoff, Scott Milligan, Richard, Haubrich, and Richard A Elion.

[The Conference on Retroviruses and Opportunistic Infections \(CROI\) Virtual: 2019 Mar 4-7: 671](#)

Poster presented at: CROI 2019. Annual Conference on Retroviruses and Opportunistic Infections; 2019 Mar 4-7; Seattle, WA



HIV Glasgow 2018

Clinical Observations of Antiretroviral (ART) Switching in HIV- suppressed Patients After Availability of TAF

Authors: Richard Elion, Joseph Eron, Steven Santiago, Paul Sax, Moti Ramgopal, Greg Huhn, Scott Milligan, Keri Althoff, and Jonathan Winston

[DOI: 10.1002/jia.2.25187: P114](#)

Poster presented at: HIV Glasgow. 2018 October 28-31; Glasgow, UK; Published in Journal of the International AIDS Society and Glasgow site



Digestive Disease Week (DDW) 2018

Behavioral and Clinical Factors and Direct Acting Antiviral (DAA) Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network

Authors: Rick Elion, Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, and Karam Mounzer

[DOI: 10.1016/S0016-5085\(18\)33670-9](#)

Oral presented at: Digestive Disease Week. 2018 June 2-5; Washington, DC

Behavioral and Clinical Factors and Direct Acting Antiviral (DAA) Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network

RECEIVED: GREGORY HUHN, RICK ELION, DUSHYANTHA JAYAWEEA, KERI ALTHOFF, JOSEPH ERON, SCOTT MILLIGAN, ANTHONY MILLS, GRAEME MOYLE, STEVEN SANTIAGO, PAUL SAX, GENE VOSKUHL, DAVID WYLES, AND KARAM MOUNZER. (SAX, ELION, MOYLE, SANTIAGO, SAX, SAX, GENE VOSKUHL, DAVID WYLES, AND KARAM MOUNZER)


The study was presented at the 2018 Digestive Disease Week (DDW) conference, June 2-5, 2018, in Washington, DC. The study was presented at the 2018 Digestive Disease Week (DDW) conference, June 2-5, 2018, in Washington, DC.

Untreated HCV in HIV/HCV Co-Infection Data from the TRIO Network

Authors: Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion

[DOI: 10.1016/S0016-5085\(18\)33931-3](#)

Poster presented at: Digestive Disease Week. 2018 June 2-5; Washington DC




The European Association for the Study of the Liver (EASL) 2018

Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network

Authors: Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion
DOI: [10.1016/S0168-8278\(18\)30723-2](https://doi.org/10.1016/S0168-8278(18)30723-2)

Poster presented at: The International Liver Congress. 53rd Annual Meeting of the European Association for the Study of the Liver; 2018 Apr 11-15; Paris, France



Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network

Authors: Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion
DOI: [10.1016/S0168-8278\(18\)30735-9](https://doi.org/10.1016/S0168-8278(18)30735-9)

Poster presented at: The International Liver Congress. 53rd Annual Meeting of the European Association for the Study of the Liver; 2018 Apr 11-15; Paris, France



HAE

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023

Barriers to Persisting on Prophylactic Treatment For C1-Esterase Inhibitor Deficient Hereditary Angioedema; Observations from Community Immunology

Authors: Jason Raasch, William R. Lumry, Scott C. Milligan, and Marc Riedl
DOI: <https://doi.org/10.1016/j.jval.2023.03.2053>

Poster presented at: ISPOR 2023 Conference; 2023 May 7-10; Boston, MA. Published in Value in Health and ISPOR site



American College of Allergy, Asthma & Immunology (ACAAI) 2022

Attack Location And Severity/Resolution In Patients With Hereditary Angioedema (HAE); Observations From Community Immunology

Authors: William R. Lumry, H. Henry Li, Scott C. Milligan, Jason Raasch, and Marc Riedl
DOI: [10.1016/j.anai.2022.08.593](https://doi.org/10.1016/j.anai.2022.08.593)

Poster presented at: American College of Allergy, Asthma & Immunology- 2022 Annual Scientific Meeting, 2022 Nov 10-14; Louisville, Kentucky



Development Of The Patient-Important Outcomes National Data Repository (PIONEER) For Hereditary Angioedema (HAE)

Authors: William R. Lumry, Joshua Jacobs, H. Henry Li, Scott C. Milligan, Maeve E. O'Connor, Jason Raasch, and Marc Riedl

DOI: [10.1016/j.anaai.2022.08.591](https://doi.org/10.1016/j.anaai.2022.08.591)

Poster presented at: American College of Allergy, Asthma & Immunology-2022 Annual Scientific Meeting, 2022 Nov 10-14; Louisville, Kentucky



IPF/PAH


Pulmonary Circulation Journal 2023

Characteristics of Patients with Pulmonary Arterial Hypertension from an Innovative, Comprehensive Real-World Patient Data Repository

Authors: Harrison W. Farber, Murali M. Chakinala, Michelle Cho, Robert P. Frantz, Andrew Frick, Lisa Lancaster, Scott Milligan, Ronald Oudiz, Sumeet Panjabi, Yuen Tsang, Steven D. Nathan

Pulmonary Circulation 13 (3): e12258. July 06, 2023

<https://doi.org/10.1002/pul2.12258>.



American Thoracic Society (ATS) 2022

Development of a Comprehensive, Integrated Patient Data Repository of US Pulmonary Hypertension (PH) Patients to Assess the Impact of Clinical Care on Patient Outcomes

Authors: H.W. Farber, S. Milligan, S. Panjabi, Y. Tsang, K. Bettencourt, and M. Cho

DOI: [10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A3997](https://doi.org/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A3997)

Poster presented at: ATS 2022 May 13-18



CHEST Annual Meeting 2021 – VIRTUAL

Comparison of Idiopathic Versus Connective Tissue Disease-Associated Pulmonary Arterial Hypertension (PAH) Groups in US Clinical Practice

Authors: Ronald J. Oudiz, MD, FCCP, Murali M. Chakinala, MD, FCCP, Robert P. Frantz, MD, Adaani E. Frost, MD, Lisa H. Lancaster, MD, FCCP, Steven D. Nathan, MBBCh, FCCP, Sumeet Panjabi, PhD, Andrew Frick, MS, and Harrison W. Farber, MD

DOI: [10.1016/j.chest.2021.07.2006](https://doi.org/10.1016/j.chest.2021.07.2006)

ePoster presented at: Virtual CHEST 2021 Conference. 2021 October 17-20.



Transthoracic Echocardiogram (ECHO) and Right Heart Catheterization (RHC) as Disease Management Tools for Patients with PAH in US Clinical Practice

Authors: Murali M. Chakinala, MD, FCCP, Robert P. Frantz, MD, Lisa H. Lancaster, MD, FCCP, Steven D. Nathan, MBBCh, FCCP, Ronald J. Oudiz, MD, FCCP, Sumeet Panjabi, PhD, Nicole Wick, and Harrison W. Farber, MD

DOI: [10.1016/j.chest.2021.07.2023](https://doi.org/10.1016/j.chest.2021.07.2023)

ePoster presented at: Virtual CHEST 2021 Conference. 2021 October 17-20.




Care and Characteristics of Patients with Pulmonary Arterial Hypertension (PAH) in US Clinical Practice

Authors: Adaani E. Frost, MD, Murali M. Chakinala, MD, FCCP, Robert P. Frantz, MD, Lisa H. Lancaster, MD, FCCP, Steven D. Nathan, MBBCh, FCCP, Ronald J. Oudiz, MD, FCCP, Sumeet Panjabi, PhD, Scott Milligan, PhD, and Harrison W. Farber, MD

DOI: [10.1016/j.chest.2021.07.1999](https://doi.org/10.1016/j.chest.2021.07.1999)

ePoster presented at: Virtual CHEST 2021 Conference. 2021 October 17-20.



International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 – VIRTUAL

Comorbid Burden and Survival Risk Metrics of Pulmonary Hypertension (PH) Patients in US-Clinical Care: Real-World Assessments from the TRIO Health PH Registry

Authors: Murali Chakinala, Deepali Rane, Ronald Oudiz, Adaani Frost, Robert Frantz, Steven Nathan, and Harrison Farber

[ISPOR Presentations Database](#)

DOI: [10.1016/j.jval.2021.04.344](https://doi.org/10.1016/j.jval.2021.04.344)

ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20. Published in Value in Health and ISPOR site



Real-World Clinical Characteristics of 112 Patients with Interstitial Lung Disease (ILD); Update from the Trio Health ILD Registry

Authors: Frantz RP, Rane D, Nathan SD, Lancaster L, Frost AE, Chakinala MM, Oudiz RJ, and Farber HW

[ISPOR Presentations Database](#)

DOI: [10.1016/j.jval.2021.04.1099](https://doi.org/10.1016/j.jval.2021.04.1099)

ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20. Published in Value in Health and ISPOR site



American Thoracic Society (ATS) 2021 VIRTUAL

Comorbid Burden and Survival Risk Metrics of Pulmonary Hypertension (PH) Patients in US-Clinical Care: Real-World Assessments from the TRIO Health PH Registry

Authors: Murali Chakinala, Deepali Rane, Ronald Oudiz, Adaani Frost, Robert Frantz, Steven Nathan, and Harrison Farber

DOI: [10.1164/ajrccm-conference.2021.203.1.MeetingAbstracts.A1594](https://doi.org/10.1164/ajrccm-conference.2021.203.1.MeetingAbstracts.A1594)

American Journal of Respiratory and Critical Care Medicine 2021; 203:A1594

ePoster presented at: ATS 2021 May 14-19



American Thoracic Society (ATS) 2020


A Platform to Combine Clinical, Prescription, And Dispensing Data to Better Inform Idiopathic Pulmonary Fibrosis Care; The Trio Registry

Authors: Steven Nathan, MD, Murali Chakinala, MD, Robert Frantz, MD, Adaani Frost, MD, Lisa Lancaster, MD, Kelsey Milligan, Scott Milligan, PhD, Ronald Oudiz, MD, and Harrison Farber, MD

DOI: [10.1164/ajrccm-conference.2020.201.1.MeetingAbstracts.A1519](https://doi.org/10.1164/ajrccm-conference.2020.201.1.MeetingAbstracts.A1519)

American Journal of Respiratory and Critical Care Medicine 2020; 201:A1519

Poster presented at: ATS 2020 May 15-20; Philadelphia, PA (Cancelled)


**The Trio Pulmonary Arterial Hypertension Registry; A Platform Combining EMR Clinical Measures with Pharmacy Prescription and Dispensing Data**

Authors: Steven Nathan, MD, Harrison Farber, MD, Murali Chakinala, MD, Robert Frantz, MD, Adaani Frost, MD, Scott Milligan, PhD, and Ronald Oudiz, MD

DOI: [10.1164/ajrccm-conference.2020.201.1.MeetingAbstracts.A6593](https://doi.org/10.1164/ajrccm-conference.2020.201.1.MeetingAbstracts.A6593)

American Journal of Respiratory and Critical Care Medicine 2020; 201:A6593

Poster presented at: ATS 2020 May 15-20; Philadelphia, PA (Cancelled)



NASH

The Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease

Authors: Joana Vieira Barbosa, MD, MSc, Scott Milligan, PhD, Andrew Frick, MSc, Jeremy Broestl, BSc, Zobair Younossi, MD, MPH, Nezam H. Afdhal, MD, and Michelle Lai, MD, MPH

DOI: [10.14309/ajg.0000000000001606](https://doi.org/10.14309/ajg.0000000000001606)

Published in: The American Journal of GASTROENTEROLOGY: Online January 18, 2022



The American Association for the Study of Liver Diseases (AASLD) 2021 VIRTUAL

The Impact of Race on NAFLD Outcomes in US Clinical Practice

Authors: Scott B. Minchenberg, Joana Vieira Barbosa, Scott Milligan, Andrew Frick, Nezam H. Afdhal, and Michelle Lai

DOI: [10.1002/hep.32188.1747](https://doi.org/10.1002/hep.32188.1747)


Poster presented at: The Liver Meeting. 72nd Annual Meeting of the American Association for the Study of Liver Diseases; 2021 Nov 12-15 VIRTUAL

**Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD**

Authors: Joana Vieira Barbosa, Scott Milligan, Andrew Frick, Jeremy Broestl, Zobair Younossi, Nezam H. Afdhal, and Michelle Lai

DOI: [10.1002/hep4.1841](https://doi.org/10.1002/hep4.1841)

Published in: Hepatology Communications: Online December 30, 2021



The American Association for the Study of Liver Diseases (AASLD) 2021 VIRTUAL

The Impact of Race on NAFLD Outcomes in US Clinical Practice

Authors: Scott B. Minchenberg, Joana Vieira Barbosa, Scott Milligan, Andrew Frick, Nezam H. Afdhal, and Michelle Lai

DOI: [10.1002/hep.32188.1747](https://doi.org/10.1002/hep.32188.1747)

Poster presented at: The Liver Meeting. 72nd Annual Meeting of the American Association for the Study of Liver Diseases; 2021 Nov 12-15 VIRTUAL

**Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD**

Authors: Joana Vieira Barbosa, Scott Milligan, Andrew Frick, Jeremy Broestl, Zobair Younossi, Nezam H. Afdhal, and Michelle Lai

DOI: [10.1002/hep4.1841](https://doi.org/10.1002/hep4.1841)

Published in: Hepatology Communications: Online December 30, 2021



The European Association for the Study of the Liver (EASL) 2020 – VIRTUAL

Association of FIB4 Score with Major Cardiovascular Events (MACE) in Real-World Populations Diagnosed with NASH or NAFLD in US Clinical Practice

Authors: Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal

[Journal of Hepatology. August 2020; 73 \(suppl 1\): Abstract #THU037](#)

Poster presented at: The Digital International Liver Congress 2020; 2020 Aug 27-29

**Association of FIB4 Score with Disease Progression in Real-World Populations Diagnosed with NAFLD/NASH or at Risk of NASH in US Clinical Practice**

Authors: Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal

[Journal of Hepatology. August 2020; 73 \(suppl 1\): Abstract #THU036](#)

Poster presented at: The Digital International Liver Congress 2020; 2020 Aug 27-29

**Use of GLP-1 Receptor Agonists (GLP1a) and/or SGLT-2 Inhibitors (SGLT2i) in Populations with NASH or at Risk of NASH in US Clinical Practice**

Authors: Michelle Lai, Jeremy Broestl, Kavita Juneja, Scott Milligan, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal

[Journal of Hepatology. August 2020; 73 \(suppl 1\): Abstract #FRI107](#)

Poster presented at: The Digital International Liver Congress 2020; 2020 Aug 27-29



International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2020- VIRTUAL

Evaluation of Liver Outcomes Relative to Use of GLP-1 Receptor Agonists (GLP1A) and/or SGLT-2 Inhibitors (SGLT2I) in Real-World Populations Diagnosed with Type II Diabetes (T2DM) and NASH/NAFLD or at Risk of Nash

Authors: Michelle Lai, Andrew Frick, Kavita Juneja, Bruce Koch, Scott Milligan, Macky Natha, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal

[DOI: 10.1016/j.jval.2020.04.365](#)

Poster presented at: Virtual ISPOR 2020 Conference. 2020 May 15-20; Published in Value in Health and ISPOR site



Lean and Obese Patients with Non-Alcoholic Steatohepatitis (NASH) / Non-Alcoholic Fatty Liver Disease (NAFLD); Comparisons of Populations and Disease Progression

Authors: Michelle Lai, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal

[DOI: 10.1016/j.jval.2020.04.363](https://doi.org/10.1016/j.jval.2020.04.363)

Poster presented at: Virtual ISPOR 2020 Conference. 2020 May 15-20;
Published in Value in Health and ISPOR site



Digestive Disease Week (DDW) 2020

Association of FIB4 Score with Major Cardiovascular Events (MACE) in Real-World Populations Diagnosed with NASH or NAFLD in US Clinical Practice

Authors: Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal

[DOI: 10.1016/S0016-5085\(20\)33833-6](https://doi.org/10.1016/S0016-5085(20)33833-6)

Oral presented online at: Digestive Disease Week. 2020 May 2-5;
Chicago, IL (Cancelled)

Association of FIB-4 score with Major Cardiovascular Events (MACE) in real-world populations diagnosed with NASH or NAFLD in US Clinical Practice

Michelle Lai¹, Jeremy Broestl², Andrew Frick³, Richard Haubrich⁴, Bruce Koch⁵, Scott Milligan⁶, Macky Natha⁷, Zobair Younossi⁸, and Nezam Afdhal⁹
¹Northwell Healthcare, ²Northwell Healthcare, ³Northwell Healthcare, ⁴Northwell Healthcare, ⁵Northwell Healthcare, ⁶Northwell Healthcare, ⁷Northwell Healthcare, ⁸Northwell Healthcare, ⁹Northwell Healthcare

Association of FIB4 Score with Disease Progression in Real-World Populations Diagnosed with NAFLD/NASH or at Risk of NASH in US Clinical Practice

Authors: Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal

[DOI: 10.1016/S0016-5085\(20\)34210-4](https://doi.org/10.1016/S0016-5085(20)34210-4)

Poster presented at: Digestive Disease Week. 2020 May 2-5; Chicago, IL
(Cancelled)



Use of GLP-1 Receptor Agonists (GLP1a) and/or SGLT-2 Inhibitors (SGLT2i) in Populations with NASH or at Risk of NASH in US Clinical Practice

Authors: Michelle Lai, Jeremy Broestl, Kavita Juneja, Scott Milligan, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal

[DOI: 10.1016/S0016-5085\(20\)34283-9](https://doi.org/10.1016/S0016-5085(20)34283-9)

Poster presented at: Digestive Disease Week. 2020 May 2-5; Chicago, IL
(Cancelled)



Digestive Disease Week (DDW) 2019

Real-World Evaluation of NASH in US Clinical Practice: Underutilization of Liver Biopsy and Liver Imaging

Authors: Michelle Lai, Scott Milligan, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Oral presented at: The International Liver Congress. 54th Annual Meeting of the European Association for the Study of the Liver; 2019 Apr 10-14; Vienna, Austria

Real-world evaluation of NASH in US Clinical Practice: Underutilization of liver biopsy and liver imaging

Michelle Lai¹, Scott Milligan², Nicole Wick³, Zobair Younossi^{1,4}, and Nezam Afdhal¹


¹Beth Israel Deaconess Medical Center, Boston, MA, ²Trio Health Analytics, ³Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, ⁴Betty and Guy Beatty Center for Integrated Research, Inova Health Systems, Falls Church, VA

The European Association for the Study of the Liver (EASL) 2019

Real-World Evaluation of NASH in US Clinical Practice: Underutilization of Liver Biopsy and Liver Imaging

Authors: Michelle Lai, Scott Milligan, Nicole Wick, Zobair Younossi, and Nezam Afdhal.

Poster presented at: The International Liver Congress. 54th Annual Meeting of the European Association for the Study of the Liver; 2019 Apr 10-14; Vienna, Austria



RHEUMATOLOGY


Journal Manuscripts - Lupus Science & Medicine

Steroid-sparing effect of belimumab: results from a retrospective observational study of real-world data

Authors: Karen Worley, Scott Milligan, Bernard Rubin

DOI: [10.1136/lupus-2023-001024](https://doi.org/10.1136/lupus-2023-001024)

Journal published in Lupus Science & Medicine 2023 Dec 22;10:e001024. doi:10.1136/lupus-2023-001024




American College of Rheumatology (ACR) Convergence 2023

Characteristics and Prior Treatment Journey of Systemic Lupus Erythematosus (SLE) Patients Who Were Prescribed Anifrolumab -- Observations from the American Rheumatology Network (ARN) in the U.S.

Authors: Vasileios Kyttaris, Gelareh Atefi, Dan Persons, Chris Ambrose, Scott Milligan, Sandra Sze-jung Wu


Poster presented at: ACR Convergence 2023, November 10-15; San Diego, California



The Effect of Belimumab on Steroid Use in Patients With SLE: Results From a Retrospective Observational Study of Real-World Data From a US Rheumatology Provider Network

Authors: Karen Worley, Scott Milligan, Bernard Rubin

Poster presented at: ACR Convergence 2023, November 10-15; San Diego, California



International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023

Reuse of Tumor Necrosis Factor Inhibitors for Treatment of Rheumatoid Arthritis despite Discordance with Patient Important Outcomes and Standard Disease Assessments

Authors: Frick A, Broestl J, Cox K, Milligan K, Persons D, Milligan S
DOI: <https://doi.org/10.1016/j.jval.2023.03.092>

Poster presented at: ISPOR 2023 Conference; 2023 May 7-10; Boston, MA. Published in Value in Health and ISPOR site



Towards Better Rheumatoid Arthritis Management by Identification of Potentially Manageable Conditions Observed with Early Discontinuation of Biologic/Targeted Synthetic (b/ts) DMARDs

Authors: Christopher Adams, Simon Helfgott, Kent Huston, Andrew Frick, Scott Milligan, Jasvinder A. Singh, Nehad Soloman, Colin C. Edgerton
DOI: <https://doi.org/10.1016/j.jval.2023.03.136>

Poster presented at: ISPOR 2023 Conference; 2023 May 7-10; Boston, MA. Published in Value in Health and ISPOR site



Are Biosimilars Equivalent To Originator Molecules In The Real-World? Assessments Of Efficacy, Toxicity, And Tolerability of Infliximabs in Infliximab-Naïve Patients With Rheumatoid Arthritis

Authors: Jasvinder A. Singh, Simon Helfgott, Kent Kwas Huston, Nehad Soloman, Andrew Frick, Scott Milligan, Colin Edgerton
DOI: <https://doi.org/10.1016/j.jval.2023.03.227>

Poster presented at: ISPOR 2023 Conference; 2023 May 7-10; Boston, MA. Published in Value in Health and ISPOR site



Persistency on Conventional Synthetic DMARDs without Evidence of Rheumatoid Arthritis Control; Identifying Populations That May Benefit from Availability of Lower-Cost TNFi Biosimilars

Authors: Frick A, Broestl J, Cox K, Milligan K, Persons D, Milligan S
DOI: <https://doi.org/10.1016/j.jval.2023.03.2336>

Poster presented at: ISPOR 2023 Conference; 2023 May 7-10; Boston, MA. Published in Value in Health and ISPOR site



American College of Rheumatology (ACR) Convergence 2022

Reasons For Early Discontinuation Of Targeted Synthetic (ts) Or Biologic (b) DMARDs; Chart Review of 20,343 Drug Episodes Given To Patients With Rheumatoid Arthritis

Authors: Kent Kwas Huston, Christopher Adams, Simon Helfgott, Jasvinder A. Singh, Nehad Soloman, Dan Persons, Scott Milligan, and Colin Edgerton

[ACR Convergence 2022: Abstract Number: 0264](#)

Poster presented at: ACR Convergence 2022; 2022 Nov 10-14; Philadelphia, Pennsylvania



Review of 167,990 Same day RAPID3, CDAI Scores for 61,312 Patients Receiving DMARD Treatment for Rheumatoid Arthritis; Evaluations of Disease Assessments and Treatment Discontinuation

Authors: Simon Helfgott, Kent Kwas Huston, Jasvinder A. Singh, Nehad Soloman, Andrew Frick, Scott Milligan, and Colin Edgerton

[ACR Convergence 2022: Abstract Number: 0927](#)

Poster presented at: ACR Convergence 2022; 2022 Nov 10-14; Philadelphia, Pennsylvania



Development of the Patient-Important Outcomes National Data Repository (PIONEER) for Rheumatic Diseases; an Enhanced Database combining Electronic Medical Data with Insight from Chart Reviews

Authors: Simon Helfgott, Kent Kwas Huston, Jasvinder A. Singh, Nehad Soloman, Jeremy Broestl, Kimmi Cox, Kelsey Milligan, and Colin Edgerton

[ACR Convergence 2022: Abstract Number: 1954](#)

Poster presented at: ACR Convergence 2022; 2022 Nov 10-14; Philadelphia, Pennsylvania



International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 – VIRTUAL

Experience with Apremilast in Treatment of Psoriatic Arthritis in US Clinical Practice; Assessments from Trio Health and the American Rheumatology Network (ARN)

Authors: Colin Edgerton, Andrew Frick, Simon Helfgott, Ken Kwas Huston, Jasvinder Singh, and Nehad Soloman

DOI: [10.1016/j.jval.2021.04.1152](https://doi.org/10.1016/j.jval.2021.04.1152)

ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20. Published in Value in Health and ISPOR site



Disparities in Targeted Immune Modulating (TIM) Treatment for Elderly Compared to Younger Patients with Psoriatic Arthritis (PSA)

Authors: Jasvinder Singh, Andrew Frick, Simon Helfgott, Kent Kwas Huston, Nehad Soloman, John Tesser, and Colin Edgerton

DOI: [10.1016/j.jval.2021.04.1154](https://doi.org/10.1016/j.jval.2021.04.1154)

ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20.
Published in Value in Health and ISPOR site



Outcomes with Infliximab and Its Biosimilars in Patients with Rheumatoid Arthritis (RA): Real-World Experience in the US

Authors: Simon Helfgott, MD, Janna Radtchenko, MBA, Nehad Soloman, MD, Kent Kwas Huston, MD, Jasvinder Singh, MD, MPH, and Colin Edgerton, MD

[ISPOR Presentations Database](#)

DOI: [10.1016/j.jval.2021.04.075](https://doi.org/10.1016/j.jval.2021.04.075)

ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20.
Published in Value in Health and ISPOR site



Increasing Use of Biologics in Treatment of Systemic Lupus Erythematosus Patients in US Clinical Practice: Real-World Observations from Trio Health and the American Rheumatology Network (ARN)

Authors: Simon Helfgott, Deepali Rane, Kent Kwas Huston, Jeremy Broestl, Jasvinder Singh, Nehad Soloman, and Colin Edgerton

[ISPOR Presentations Database](#)

ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20.
Published in Value in Health and ISPOR site




Real-World Utilization of Janus Kinase Inhibitors (JAKs) and Biologics in Patients with Rheumatoid Arthritis (RA)

Authors: Jasvinder A. Singh, MD, MPH, Janna Radtchenko, MBA, Nehad Soloman, MD, Kwas Huston, MD, Simon M. Helfgott, MD, and Colin C. Edgerton, MD

[ISPOR Presentations Database](#)

DOI: [10.1016/j.jval.2021.04.678](https://doi.org/10.1016/j.jval.2021.04.678)

ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20.
Published in Value in Health and ISPOR site



Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN)

Authors: Nehad Soloman, Mona Amin, Kimmi Cox, Simon Helfgott, Alexander Hu, Kent Kwas Huston, Jordan Leonard, Scott Milligan, Jasvinder Singh, John Tesser, and Colin Edgerton

[ISPOR Presentations Database](#)

DOI: [10.1016/j.jval.2021.04.681](https://doi.org/10.1016/j.jval.2021.04.681)

ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20.
Published in Value in Health and ISPOR site



Management of Gout after Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)

Authors: Nehad Soloman, Mona Amin, Simon Helfgott, Alexander Hu, Kent Kwas Huston, Jordan Leonard, Kelsey Milligan, Scott Milligan, Jasvinder Singh, John Tesser, and Colin Edgerton

[ISPOR Presentations Database](#)

DOI: [10.1016/j.jval.2021.04.682](https://doi.org/10.1016/j.jval.2021.04.682)

ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20.
Published in Value in Health and ISPOR site



Academy of Managed Care Pharmacy (AMCP) 2021 VIRTUAL

Real-World Utilization of Janus Kinase Inhibitors (JAKs) and Biologics in Patients with Rheumatoid Arthritis (RA)

Authors: Janna Radtchenko, Jasvinder A. Singh, MD, MPH, Nehad Soloman, MD, Kwas Huston, MD, Simon M. Helfgott, MD, and Colin C. Edgerton, MD

DOI: [10.18553/jmcp.2021.27.4-a.s1](https://doi.org/10.18553/jmcp.2021.27.4-a.s1)

Journal of Managed Care + Specialty Pharmacy 2021 Apr; 27(4-a Suppl): S103-M9

ePoster presented at: AMCP Managed Care and Specialty Pharmacy Annual Meeting, 2021 Apr 12-16 and published in Journal of Managed Care + Specialty Pharmacy



American College of Rheumatology (ACR) Convergence 2020 - VIRTUAL

Real-World Utilization of Infliximab (IFX) and Its Biosimilars in Patients (Pts) with Rheumatoid Arthritis (RA) Since the First Biosimilar Approval in the US

Authors: Simon Helfgott, Janna Radtchenko, Nehad Soloman, Kent Kwas Huston, Jasvinder Singh, and Colin Edgerton

[Arthritis Rheumatol. 2020; 72 \(suppl 10\)](#)

Poster presented at: Virtual ACR Convergence 2020 Conference. 2020 Nov 5-9



Increasing Use of Biologics in Treatment of Systemic Lupus Erythematosus Patients in US Clinical Practice: Real-World Observations from Trio Health and the American Rheumatology Network

Authors: Simon Helfgott, Jeremy Broestl, Kent Kwas Huston, Deepali Rane, Jasvinder Singh, Nehad Soloman, and Colin Edgerton

[Arthritis Rheumatol. 2020; 72 \(suppl 10\)](#)

Poster presented at: Virtual ACR Convergence 2020 Conference. 2020 Nov 5-9



Management of Gout After Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)

Authors: Nehad Soloman, Mona Amin, Simon Helfgott, Alexander Hu, Kent Kwas Huston, Jordan Leonard, Kelsey Milligan, Scott Milligan, Jasvinder Singh, John Tesser, and Colin Edgerton
[Arthritis Rheumatol. 2020; 72 \(suppl 10\)](#)


Poster presented at: Virtual ACR Convergence 2020 Conference. 2020 Nov 5-9



Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN)

Authors: Nehad Soloman, Mona Amin, Kimmi Cox, Simon Helfgott, Alexander Hu, Kent Kwas Huston, Jordan Leonard, Scott Milligan, Jasvinder Singh, John Tesser, and Colin Edgerton
[Arthritis Rheumatol. 2020; 72 \(suppl 10\)](#)

Poster presented at: Virtual ACR Convergence 2020 Conference. 2020 Nov 5-9



Experience with Apremilast in Treatment of Psoriatic Arthritis in US Clinical Practice; Assessments from Trio Health and the American Rheumatology Network (ARN)

Authors: Colin Edgerton, Andrew Frick, Simon Helfgott, Kent Kwas Huston, Jasvinder Singh, and Nehad Soloman
[Arthritis Rheumatol. 2020; 72 \(suppl 10\)](#)

Poster presented at: Virtual ACR Convergence 2020 Conference. 2020 Nov 5-9



The “Why” of Drug Discontinuation; Clinical Review of EMR Notes for 2,545 Patients with Rheumatic Diseases

Authors: Kent Kwas Huston, Simon Helfgott, Scott Milligan, Jasvinder Singh, Nehad Soloman, Brandon Weil, and Colin Edgerton
[Arthritis Rheumatol. 2020; 72 \(suppl 10\)](#)


Poster presented at: Virtual ACR Convergence 2020 Conference. 2020 Nov 5-9



Change in Utilization of Outpatient Services at US Community Rheumatology Practices During COVID-19 Outbreak

Authors: Kent Kwas Huston, Nehad Soloman, Janna Radtchenko, Simon Helfgott, Jasvinder Singh, and Colin Edgerton
[Arthritis Rheumatol. 2020; 72 \(suppl 10\)](#)

Poster presented at: Virtual ACR Convergence 2020 Conference. 2020 Nov 5-9



International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2020 – VIRTUAL

Outpatient Costs in Rheumatoid Arthritis (RA) Patients With VS Without Comorbidities**Authors:** Edgerton CC, Radtchenko J, and Holers VMDOI: [10.1016/j.jval.2020.04.691](https://doi.org/10.1016/j.jval.2020.04.691)

Value in Health. 2020; 23 (suppl 1): S214


Poster presented at: Virtual ISPOR 2020 Conference. 2020 May 15-20



American College of Rheumatology (ACR) 2019

Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices**Authors:** Colin C. Edgerton, Janna Radtchenko, and V. Michael Holers[Arthritis Rheumatol. 2019; 71 \(suppl 10\): Abstract #1138](#)

Poster presented at: American College of Rheumatology/ The Association of Rheumatology Professionals (ACR/ARP) Annual Meeting. 2019 November 8-13; Atlanta, GA




RARE DISEASES


National Organization for Rare Disorders (NORD) 2019

Misdiagnosis of Desmoid Tumors; Insight from the Desmoid Tumor Research Foundation (DTRF) Patient Registry**Authors:** Kelly Mercier, Lynn Hernandez, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, and Kelsey Milligan

Poster presented at: NORD Rare Summit. 2019 October 21-22; Washington DC

**Quality of Life in Pediatric Patients with SYNGAP1-Related Non-Syndromic Intellectual Disability (NSID); Data from the SYNGAP1 (MRD5) Patient Registry****Authors:** Weldon M, Holder J, Rumbaugh G, Smith-Hicks C, Boulanger V, Seebald A, Rossov S, Milligan K


Poster presented at: NORD Rare Summit. 2019 October 21-22; Washington DC



The PKU Patient Registry: Understanding the Natural History of PKU

Authors: Olaf Bodamer MD PhD, Harvey Levy MD, Eileen Blakely, Christine Brown, Hilary Feldman, Rhonda Connolly, Kathryn Moseley, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Kelsey Milligan, and Janna Radtchenko

Poster presented at: NORD Rare Summit. 2019 October 21-22; Washington DC




European Hematology Association (EHA) 2019

Quality of Life and Demographics of Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry

Authors: Caroline Kruse, Alexandra Kruse, Nancy Potthast, Vanessa Boulanger, Allison Seebald, Suzanne Rossov and Kelsey Milligan.

DOI: [10.1097/01.HS9.0000567492.92876.8b](https://doi.org/10.1097/01.HS9.0000567492.92876.8b)

Poster presented at: EHA 2019. The 24th Congress of the European Hematology Association; 2019 June 13-16; Amsterdam, The Netherlands



Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019

Quality of Life (QOL) and Tumor Location in Patients with Desmoid Tumors; Data From The Desmoid Tumor Research Foundation (DTRF) Natural History Study

Authors: Kelly Mercier, Lynne Hernandez, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, and Kelsey Milligan

DOI: [10.1200/JCO.2019.37.15_suppl.e18291](https://doi.org/10.1200/JCO.2019.37.15_suppl.e18291) *Journal of Clinical Oncology* 37, no. 15 suppl

Poster presented at: ASCO 2019. The 55th Annual Meeting of the American Society of Clinical Oncology; 2019 May 31 - June 4; Chicago, Illinois



International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019

Understanding Disease and Burden in Syngap1-Related Non-Syndromic Intellectual Disability (NSID) Using a Patient Registry Database

Authors: Weldon M, Holder J, Rumbaugh G, Smith-Hicks C, Boulanger V, Seebald A, Rossov S, Milligan K, and Radtchenko J

DOI: [10.1016/j.jval.2019.04.1689](https://doi.org/10.1016/j.jval.2019.04.1689)

Poster presented at: ISPOR 2019 Conference; 2019 May 18-22; New Orleans, LA. Published in Value in Health and ISPOR site



Understanding Real-World Treatment Patterns and Quality of Life in Patients with Pemphigus and Pemphigoid Using a Patient Registry Database

Authors: Yale ML, Boulanger V, Seebald A, Rossov S, Milligan K, and Radtchenko J.

DOI: [10.1016/j.jval.2019.04.1697](https://doi.org/10.1016/j.jval.2019.04.1697)

Poster presented at: ISPOR 2019 Conference; 2019 May 18-22; New Orleans, LA. Published in Value in Health and ISPOR site



The Use of Patient Registry to Better Inform Healthcare Decision Makers and Improve Clinical Outcomes for Patients with Phenylketonuria (PKU)

Authors: Bodamer O, Levy H, Blakely E, Brown C, Feldman H, Connolly R, and Moseley K.

DOI: [10.1016/j.jval.2019.04.1701](https://doi.org/10.1016/j.jval.2019.04.1701)

Poster presented at: ISPOR 2019 Conference; 2019 May 18-22; New Orleans, LA. Published in Value in Health and ISPOR site



The Use of Patient Reported Registry Data to Improve Health Outcomes for Patients with Opsoclonus Myoclonus Syndrome (OMS)

Authors: Michaelis M, Khoury-Dennis C, Boulanger V, Seebald A, Rossov S, Milligan K, and Radtchenko J.

DOI: [10.1016/j.jval.2019.04.1698](https://doi.org/10.1016/j.jval.2019.04.1698)

Poster presented at: ISPOR 2019 Conference; 2019 May 18-22; New Orleans, LA. Published in Value in Health and ISPOR site




National Institute of Health (NIH) 2019

Understanding Demographics and Diagnosis in Syngap1-related Non-Syndromic Intellectual Disability (NSID) Patients Using a Patient Registry Database

Authors: Weldon M, Holder J, Rumbaugh G, Smith-Hicks C, Boulanger V, Seebald A, Rossov K and Milligan K.

The Power of Patients: Informing Our Understanding of Rare Diseases: Posters and Acknowledgements

Poster presented at: Rare Disease Day at NIH 2019; 2019 February 28; Bethesda, MD



National Organization for Rare Disorders (NORD) 2018

The Opsoclonus Myoclonus Syndrome (OMS) Registry: A Vehicle to Better Understand the Natural History and Experience of OMS Patients

Authors: Mike Michaelis, Christy Khoury-Dennis, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko

Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



Symptoms and Diagnosis of Opsoclonus Myoclonus Syndrome (OMS): Early Data from the OMS Registry

Authors: Mike Michaelis, Christy Khoury-Dennis, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko

Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



Treatment Utilization by Patients with Opsoclonus Myoclonus Syndrome (OMS): Insights from the OMS Registry

Authors: Mike Michaelis, Christy Khoury-Dennis, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko

Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



NORD RareCare® Assistance Programs: Helping the Rare Disease Community Access Diagnostics and Care

Authors: Jill Pollander, Pamela Gavin, and Jeremy Broestl


Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



The Pemphigus-Pemphigoid Registry: Real-World Diagnostic and Treatment Patterns

Authors: Marc L. Yale, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko


Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



The Pemphigus-Pemphigoid Registry: First Report of Patient Quality of Life Measures

Authors: Marc L. Yale, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko


Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



The Pemphigus-Pemphigoid Registry: A Platform to Improve Understanding and Advance Care

Authors: Marc L. Yale, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko


Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



The PKU Patient Registry: A Step for Better Disease Awareness and Improved Patient Outcomes

Authors: Eileen Blakely, Christine Brown, Olaf Bodamer, Harvey Levy, Hilary Feldman, Rhonda Connelly, Kathryn Moseley, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko


Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



The PKU Patient Registry: Understanding Diagnosis and Medical History of Patients with PKU

Authors: Eileen Blakely, Christine Brown, Olaf Bodamer, Harvey Levy, Hilary Feldman, Rhonda Connelly, Kathryn Moseley, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan and Janna Radtchenko


Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



The PKU Patient Registry: Evaluating Treatment Paradigms of Patients with PKU

Authors: Eileen Blakely, Christine Brown, Olaf Bodamer, Harvey Levy, Hilary Feldman, Rhonda Connelly, Kathryn Moseley, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko

Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



ARTICLES

The Next Chapter for Real World Evidence: Validating Data with the Patient Voice

Tandon, Ramita
PharmaVoice (November/December 2020): Page 31



Coverage Denials Eyed in Surging HCV Rx Nonstarts

Shaw, Gina.
Specialty Pharmacy Continuum 6 (Mar/Apr 2017): Cover,15

